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Genomweite Assoziationsstudien (GWAS) haben dazu beigetragen eine Vielzahl 
genetischer Varianten zu identifizieren, die mit dem Risiko komplexer Krankheiten 
assoziiert sind. Die überhaupt erste erfolgreiche GWAS wurde von Klein et al. im Jahre 
2005 durchgeführt und detektierte eine Assoziation genetischer Varianten im 
Komplement Faktor H (CFH) Gen mit der altersabhängigen Makuladegeneration 
(AMD). AMD ist eine komplexe Netzhauterkrankung und weltweit eine der häufigsten 
Ursachen für Sehbeeinträchtigungen und Erblindungen. Es wird angenommen, dass 
sowohl Umweltfaktoren, insbesondere Altern und Rauchen, als auch die genetische 
Prädisposition das Krankheitsrisiko wesentlich bestimmen. Der Einfluss genetischer 
Faktoren wurde auf 40 - 71 % geschätzt. Bisher ist nur wenig über die Ätiologie der 
AMD bekannt, obwohl die aktuellste GWAS von Fritsche et al. (2016) bereits 52 
unabhängige Signale in 34 mit AMD-assoziierten Loci aufdecken konnte. 
Die meisten der AMD-assoziierten Varianten befinden sich in nicht-kodierenden 
intergenischen oder intronischen Bereichen des Genoms, wobei eine funktionelle 
Abklärung eine große Herausforderung darstellt. Solche Varianten könnten sich auf 
die Regulation der Genexpression auswirken. Aus diesem Grund bestand das Ziel 
dieser Arbeit darin, die Pathogenese der AMD im Kontext von Effekten auf die 
Regulation der Genexpression zu betrachten. 
In einem ersten Ansatz wurden „expression quantitative trait loci“ (eQTLs) in 
Lebergewebe untersucht. Dafür wurden Genotyp- und Genexpressionsdaten von vier 
unabhängigen Studien in einer zusammenführenden Analyse betrachtet. Alle 
miteinbezogenen Studien und Proben durchliefen ein eigens hierfür entwickelten 
Datenverarbeitungsprotokoll, das vor allem auf die Identifikation reproduzierbarer 
Effekte fokussiert war. Insgesamt wurden Daten von 588 Individuen untersucht und es 
konnten 7.612 Gene gefunden werden, die signifikant (Q-Wert < 0,05) von genetischen 
Varianten reguliert werden. Bemerkenswerterweise zeigten sich 15 dieser Gene von 
AMD-assoziierten Varianten beeinflusst und eine vergleichende Analyse ergab, dass 
diese Gene vor allem in Zusammenhang mit Prozessen des angeborenen 
Komplementsystems und des Metabolismus von Lipoproteinen stehen.  
In einem zweiten Projekt wurden die Daten der „Genotype-Tissue Expression“ (GTEx) 
Datenbank ausgewertet, um die initialen Untersuchungen auf eine Vielzahl an 
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Geweben zu erweitern. GTEx beinhaltet Daten zu 48 unterschiedlichen Geweben bzw. 
Zelltypen, die von bis zu 500 Spendern zur Verfügung stehen. Die eQTL Analyse 
ermöglichte es, eine neue Hypothese bezüglich genregulatorischer Effekte in einem 
der am stärksten mit AMD assoziierten Loci aufzustellen. So zeigte sich, dass 
genetische Varianten innerhalb des ARMS2-HTRA1 Locus Gene regulieren, die sich 
an unterschiedlichsten Positionen des Genoms befinden und deren Genprodukte 
größtenteils an Immunsystem-bezogenen Prozessen teilnehmen. Zusätzlich zu den 
bioinformatischen Untersuchungen wurden in vitro Experimente durchgeführt, um die 
erarbeitete Hypothese zu valideren. In einer ersten Untersuchung wurde dazu eine 
Deletion innerhalb des ARMS2-HTRA1 Locus herbeigeführt und betrachtet, ob dies 
die Genexpression der vorhergesagten Zielgene beeinflusst. Außerdem wurde in 
weiteren Experimenten die Genexpression innerhalb des ARMS2-HTRA1 Locus 
gezielt verstärkt. Beide Ansätze konnten jedoch in den initialen Experimenten die 
aufgestellte Hypothese in HEK293T Zellen nicht bestätigen. 
In einem weiteren Projekt wurde eine eQTL Analyse von 314 gesunden retinalen 
Gewebeproben durchgeführt, die von drei unabhängigen Instituten gesammelt 
wurden. Dabei konnten 9.733 Gene identifiziert werden, die signifikant von 
genetischen Varianten reguliert werden (Q-Wert < 0,05). Diese zusammenfassende 
Studie ermöglichte zum ersten Mal eine Analyse der Genexpressionsregulation in 
ausschließlich gesunden Netzhautproben. Interessanterweise zeigten jedoch nur 7 der 
34 AMD-assoziierten Loci eQTL in der Retina, obwohl man davon ausgehen muss, 
dass dieses Gewebe ein Ort der primären/sekundären Pathologie der AMD ist. 
Aus diesem Grund zielte das abschließende Projekt darauf ab, ein 
zusammenhängendes Bild der Genexpressionsregulation im Lichte der AMD Genetik 
zu erhalten. Dafür wurde eine transkriptomweite Assoziationsstudie (TWAS) 
durchgeführt, die die Genotypen von 16.144 AMD Patienten und von 17.832 gesunden 
Vergleichspersonen aus dem Datensatz des internationalen AMD Genomics 
Consortium (IAMDGC) miteinschloss. Für alle Proben wurde die individuelle 
Genexpression in 27 Geweben vorhergesagt und mit dem AMD-Status verglichen. 
Insgesamt konnten 106 Gene identifiziert werden, die sich in mindestens einem 
Gewebe mit der AMD assoziiert zeigten. Diese Analyse deckte genregulatorische 
Effekte in 25 der 34 AMD-assoziierten Loci auf. 
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Zusammengefasst zeigen die Ergebnisse dieser Arbeit, dass die Regulation der 
Genexpression ein häufiges Phänomen in AMD-assoziierten Loci darstellt. Die 
Resultate verdeutlichen eine Beteiligung systemischer Prozesse, wie zum Beispiel des 
Komplementsystems und der Blut-Lipoproteine, an der AMD Pathogenese. Außerdem 
konnte die Analyse AMD-assoziierter Gene zeigen, dass diese nicht ausschließlich in 
der Retina, sondern häufig ubiquitär reguliert werden. So ist es wahrscheinlich, dass 
die zugrundeliegenden Prozesse der AMD Pathogenese im gesamten Körper 
ablaufen, wobei es offensichtlich fast ausschließlich zur Expression eines Phänotyps 





Genome-wide association studies (GWAS) have led to the identification of a plethora 
of risk-associated genetic variants for a multitude of complex diseases. The very first 
GWAS was performed by Klein et al. in the year 2005 and identified variants in the 
complement factor H (CFH) gene to be associated with age-related macular 
degeneration (AMD). AMD is a complex eye disease and one of the most common 
causes of visual impairments and blindness worldwide. It is widely accepted that 
environmental factors, especially advanced age and smoking, as well as genetic 
factors contribute substantially to disease risk. Remarkably, the influence of genetics 
was estimated to be as high as 40-71 %. However, little is known about AMD aetiology, 
although the latest GWAS performed by Fritsche et al. (2016) revealed 52 independent 
signals distributed over 34 loci to be associated with AMD. 
Most of the AMD-associated variants are located in non-coding intergenic or intronic 
regions of the genome, where functional annotation presents a major challenge. 
However, these variants may play an important role in the regulation of gene 
expression. The aim of this thesis was therefore to examine the pathogenesis of AMD 
in the context of gene expression regulation. 
A first approach investigated expression quantitative trait loci (eQTL) in liver tissue. 
Thus, genotype and gene expression data from four independent studies were 
combined to enable a comprehensive analysis. All samples and studies underwent an 
especially developed data processing protocol, which applied stringent filter to 
exclusively allow the detection of highly valid associations. Altogether 588 samples 
were included and 7,612 genetically regulated genes (Q-Value < 0.05) have been 
identified. Remarkably, 15 of these are influenced by AMD-associated variants and a 
comparative analysis reinforced the notion that the initial complement system and 
lipoprotein metabolism play a role in AMD pathogenesis. 
In a second project, the Genotype-Tissue Expression (GTEx) database was explored 
to extend the initial investigations to a variety of tissues. GTEx contains data on 48 
different tissues or cell types available from up to 500 donors. The eQTL analysis 
enabled a new hypothesis regarding gene expression regulatory effects in one of the 
most significant AMD-associated loci. It was shown that genetic variants within the 
ARMS2-HTRA1 locus regulate immune system related genes throughout the whole 
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genome. In addition to the bioinformatics studies, in vitro experiments were conducted 
to validate the developed hypothesis. First, a large genomic deletion within the 
ARMS2-HTRA1 locus was introduced to assess potential consequences on the 
expression of bioinformatical predicted target genes. In a second approach, gene 
expression within the locus was enhanced by targeted application of transcription 
activation factors. Nevertheless, both strategies were not able to confirm the generated 
hypothesis in HEK293T cells in the initial experiments. 
The next project included the comprehensive analysis of eQTL in 314 healthy retinal 
tissue samples collected from three independent study sites. Altogether, 9,733 
genetically regulated genes (Q-value < 0.05) were identified, which allowed insights in 
gene expression regulation of exclusively healthy retinal tissues for the very first time. 
Interestingly, only 7 of 34 AMD-associated loci revealed eQTL effects in retina although 
one must assume that this tissue is a site of the primary/secondary pathology of AMD 
Therefore, the last project of this thesis aimed at obtaining a comprehensive view on 
gene expression regulation in the light of AMD genetics. A transcriptome wide 
association study (TWAS) was performed, which included the genotypes of 16,144 
late-stage AMD cases and 17,832 healthy controls from the International AMD 
Genomics Consortium (IAMDGC). For all these individuals, gene expression was 
imputed in 27 tissues and analysed in regard to the respective AMD status. This 
analysis discovered 106 genes, which expression was found to be associated with 
AMD genetics in at least one tissue. Regulatory effects on gene expression were 
identified in 25 of the 34 AMD-associated loci. 
Taken together, this work revealed that gene expression regulation is common in AMD-
associated loci. The identified genes reinforce the notion that systemic processes like 
the complement system or blood lipid levels seem to be relevant for AMD pathology. 
Furthermore, expression of genes associated with AMD is not restricted to retinal 
tissue, but instead is rather ubiquitous suggesting processes underlying AMD 






1.1 Age-related macular degeneration 
Age-related macular degeneration (AMD) is one of the most common causes of 
blindness in industrialised countries. The worldwide prevalence of AMD reaches 8.67 
% in the age group of 30 – 97 years. It is further estimated that the number of AMD 
cases increases from recently around 196 million to 288 million by the year 2040 [1]. 
The clinical phenotype of AMD manifests in the retina and can be broadly divided into 
three disease stages progressing from early AMD to intermediate AMD and finally to 
the late stage forms [2]. In healthy individuals, visual perception is accomplished in the 
retina by a complex interplay of hierarchically connected cell types, initiated by the 
photoreceptors, the primary recipients of photons. This process requires a high 
metabolic activity und needs a well-regulated support system, which comprises the 
mono-layered retinal pigment epithelium (RPE) and the blood supply, the choroid 
including the choriocapillaris (Figure 1 A).  
 
Figure 1: Schematic overview of the human retina and pathological changes caused by AMD. 
(A) Schematic overview of healthy retinal tissue, supported by the retinal pigment epithelium (RPE) and 
the chorid. (B) Changes in the retina and Drusen formation caused by early AMD. (C) Schematic 
changes in a late-stage AMD affected eye. Choroidal neovascularization is characterised by new blood 
vessels growing from the choroid into the RPE. The following hemorrhages initiate photoreceptor cell 
death and cause perturbation of the retinal layers. (Figure modified from Swaroop et al. (2009) [3])  
Early AMD is accompanied by the formation of extracellular protein-lipid aggregates, 
known as Drusen, between the RPE and Bruch`s membrane, a five-layered 
extracellular matrix structure (Figure 1 B). The lesions primarily occur around the 
macula, a region near the centre of the retina, which contains mainly cone 
photoreceptor cells and is responsible for central, high resolution colour vision. 
Nevertheless, early AMD is the most common and the least severe form of AMD and 
Introduction 
7 
is usually not recognised by the patients. Subsequently, Drusen grow in size and 
pigmentary abnormalities accumulate, resulting in the progress from the early form to 
the intermediate AMD, which still only leads to minor visual impairments such as the 
beginning loss of central vision. Finally, the late-stage AMD lesions present as two 
distinct forms, which can occur separately or combined, namely geographic atrophy 
(GA) and choroidal neovascularization (CNV). In eyes affected by GA, Drusen growth 
continues and severely hinders RPE function, which in-turn causes severe damage to 
the photoreceptors. GA is slowly progressing over years and progressively impairs 
vision. In contrast, CNV, is characterised by the formation of new fragile blood vessels 
growing from the choroid into the RPE (Figure 1 C). This leads to rapid loss of vision, 
caused by bleedings into the retinal and subretinal space. So far, only treatment 
options for CNV are available through ocular injection of inhibitors targeting the 
vascular endothelial growth factor (VEGF). However, this treatment exclusively 
addresses symptoms of the disease but cannot cure the phenotype [4,5].  
While the main manifestations of AMD affect the back of the eye, several studies 
investigated AMD patients in regard to extraocular phenotypes and potential 
biomarkers. Such studies showed lower complement Factor H (CFH) levels in the 
serum of AMD patients, which is supposed to result in an increased activation of the 
innate immune system [6,7]. Furthermore, elevated high-density lipoprotein (HDL) 
levels were found to be associated with late-stage AMD [8,9]. 
In general, little is known about AMD aetiology although three main factors seem to be 
generally accepted as AMD risk contributors: (1) Advanced age, (2) environmental 
factors, particularly smoking, and (3) genetic predisposition [10–12]. The interplay of 
environmental risk factors and genetic influences makes AMD to a so-called complex 
disease. 
1.2 The genetics of AMD 
Genetic predisposition to AMD was first investigated in the early twenty-first century. 
Remarkably, a twin study by Seddon et al. (2005) estimated the genetic contribution to 
AMD to be as high as 71 % [13]. As AMD shows a high prevalence in the general 
population, it is assumed to be influenced by many common genetic variants together 
contributing to disease risk [14].  
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A ground-breaking development in the research of complex diseases was the rise of 
large-scale genome-wide association studies (GWAS). GWAS investigate genetic 
variation in hundreds to thousands of individuals and aim to identify statistically 
significant changes in allele frequencies between a study population and a population 
of control individuals. The identified genetic variants are then assumed to be 
associated with the disease or phenotype of interest. GWAS are a hypothesis free 
approach and are well suited to identify unknown genomic loci. The first successful 
GWAS was performed by Klein et al. in 2005 and included 96 patients and 50 controls 
[15]. Remarkably, this study identified a strong association of the CFH locus on 
chromosome 1q31 with AMD and therefore raised the hypothesis of the complement 
system being involved in AMD pathogenesis. Over time, GWAS steadily increased in 
sample size and consequently identified variants with smaller effect sizes [16,17]. The 
most recent GWAS regarding late-stage AMD was conducted by the International AMD 
Genomics Consortium (IAMDGC) and included 16,144 patients and 17,832 controls 
[18]. This GWAS identified 52 independent genetic variants at 34 loci associated with 
AMD at genome wide significance (P-value < 5.0 x 10-08). Fritsche et al. (2016) 
validated the findings in the CFH locus (Figure 2 A) and further demonstrated 7 
additional independent hits (IHs) located on chromosome 1q31 - mostly representing 
rare variants with minor allele frequency (MAF) below 1 %. The 1q31 locus 
compromises, besides CFH, five CFH-related genes (CFHR1 – CFHR5). These share 
high sequence similarities with CFH and are thought to compete with CFH for binding 





Figure 2: LocusZoom plot of the most significant AMD-associated loci. 
Fritsche et al. (2016) conducted a GWAS including 16,144 AMD patients and 17,832 healthy controls. 
The association signals within the two most signifcant AMD-associated loci were plotted using 
LocusZoom [20] and the GWAS summary statistics [18]. Each dot represents one genetic variant and 
is plotted according to its AMD-association displayed by its -log10(P-value). Linkage disequlibrum (LD) 
with the respective lead variant (purple) is symbolised by a color range from red (R2 = 1) to dark blue 
(R2 = 0). Genes located within the locus are depicted on the bottom. (A) LocusZoom plot of the CFH 
locus (chromosome 1q31). (B) LocusZoom plot of the ARMS2-HTRA1 locus (chromosome 10q26). 
(Figure created using LocusZoom [20] based on the GWAS summary statistics from Fritsche et al. 
(2016) [18]) 
The second most significant AMD-associated locus is positioned on chromosome 
10q26 and was also identified in 2005 [21]. Since its discovery, the so called ARMS2-
HTRA1 locus was frequently investigated because of its high effect size. An individual 
carrying one additional C allele of the lead variant rs3750846 has an increased risk of 
developing AMD by 2.93 times [18]. Remarkably, the C allele is very common in the 
European population (MAF 20.8 %) and its frequency was found to range around 43.6 
% in AMD patients. Despite its large effect size and the strong AMD-association (P-
value 6.0 x 10-645 in [18]), little is known about the biological mechanisms underlying 
the GWAS signal at the ARMS2-HTRA1 locus (Figure 2 B). Neither ARMS2 nor 
HTRA1, the two genes located around rs3750846, were unambiguously shown to 
contribute in AMD pathogenesis [22–24]. Recently, Grassmann et al. (2017) performed 
a haplotype analysis based on the IAMDGC data narrowing the association signal to a 
small region of around 5 kbp, called the “minimal haplotype” [25]. Nevertheless, the 




1.3 The GWAS era 
After the very first successfully conducted GWAS in 2005 [15] this approach was 
applied to many other complex diseases. These include inter alia neurological 
diseases, like Alzheimer's disease (AD) [26] or Schizophrenia [27], but also other 
complex eye diseases, e.g. primary open-angle glaucoma [28] or Myopia [29]. 
However, GWAS are not restricted to diseases and were applied to a large number of 
complex phenotypes, including eye colour, height, or blood lipid levels [30–32]. 
Because of the continuously increasing number of studies, the NHGRI-EBI GWAS 
Catalog has taken on the task of collecting and storing GWAS results. Remarkably, in 
September 2018, the repository contained data from 5,687 GWAS comprising 71,673 
variant-phenotype associations [33]. The tremendous increase of GWAS loci during 
the course of time is visualised in Figure 3.  
 
Figure 3: GWAS loci mapped to chromsome 1 during the time period from 2005 to 2019. 
The NHGRI-EBI GWAS Catalog collects GWAS results of various complex phenotypes. Shown are the 
identified GWAS loci on chromosome 1 from 2005 (left) to 2019 (right) at the following time-points: 2005 
(fourth quarter), 2010 (first quarter), 2015 (first quarter), 2017 (first quarter), and 2019 (first quarter). 
Each dot represents one complex phenotype and is colored in respect to predefined groups of potentially 
related phenotypes. (The plotted data were retrieved from the GWAS catalog online repository [33]) 
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Today, thousands of loci are known to be associated with a multitude of complex 
phenotypes. In addition, large databases like the UK biobank [34] aim to recruit 
hundreds of thousands of participants and are likely facilitating the identification of 
even more GWAS loci. As already mentioned, GWAS aim to identify associated 
genomic regions but are not suited to draw further conclusions about the underlying 
biology of the signal. The interpretation of GWAS results is limited by several factors. 
Due to the extensive linkage disequilibrium (LD) of neighbouring variants in GWAS loci 
it is usually impossible to classify the signal causing variant (Figure 2). Furthermore, 
GWAS variants are often located in non-coding or intergenic regions of the genome 
[35,36]. Regarding AMD, altogether 7,218 genome-wide significant variants were 
identified and statistically fine mapped to a set of 1,345 credible variants [18,37]. Solely 
1.9 % of these variants (25 of 1,345) are potentially protein coding and thus modifying 
the amino acid sequence [18]. Therefore, the associated gene within a GWAS locus 
frequently remains difficult to determine from the GWAS signal.  
Taken together, GWAS are a successful and popular approach to identify genomic 
regions associated with complex phenotypes. Today, innovative follow up studies are 
required to enable a deeper understanding of the functional meaning of such 
association signals. 
1.4 Gene expression regulation in GWAS loci 
One attractive approach to overcome the above described limitations of GWAS results 
is to correlate the genotypes of variants, which are associated with disease at genome-
wide significance, with mRNA expression in a given tissue using large-scale mRNA 
expression studies. This type of analysis results in data known as expression 
Quantitative Trait Loci (eQTL) [38]. eQTL may become evident as local (cis) or distant 
(trans) effects (Figure 4). Local eQTL implicate that the variant (the so-called eVariant) 
is located in direct neighbourhood to the affected gene (the so-called eGene) or within 
the gene body. Local genotype variation possibly affects gene expression by altering 
transcription factor binding, splicing, DNA methylation or other molecular mechanisms 
[39]. An altered gene expression usually leads to changes in spatial or temporal 
transcript levels [40] and thereby possibly influences further genes, located anywhere 
in the genome. These indirect effects of genomic variants are called distant eQTL and 
show typically smaller effect sizes than local eQTL (Figure 4). 
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Figure 4: eQTL and their 
modes of action.  
Local eQTL variants 
(eVariants) influence gene 
expression of nearby 
genes (eGenes). Distant 
eQTL effects can be 
caused if the potentially 
regulated gene product 
itself carries out regulatory 
functions. (Figure modified 







eQTL studies have proven to be a valuable resource to follow up on GWAS results, 
since they allow the prioritisation of variants and genes in GWAS loci. Furthermore, 
eQTL databases are usually covering the whole genome and transcriptome. Their 
assessment is therefore not restricted to the evaluation of distinct GWAS results and 
can also be used to find potential commonalities of complex phenotypes or traits. Such 
pleiotropic effects could reveal pathways contributing to disease aetiology. 
Nevertheless, eQTL studies are usually based on healthy tissue and do not allow to 
draw simple implications for pathomechanisms after disease onset. 
During the last decade, a large number of studies have investigated eQTL in various 
tissues [41–44]. The data are usually collected using high throughput platforms, such 
as genotyping chips to assess the genotypes of the samples and expression 
microarrays or RNA sequencing (RNA-Seq) to measure the expression of gene 
transcripts in a given cell type or tissue. Nevertheless, it has become clear that the 
analysis of single tissue eQTL has limitations, specifically regarding sensitivity and 
specificity due to a limited statistical power [45]. Furthermore, gene expression may 
vary between tissues and cell types [46]. Single tissue eQTL studies can miss 
important signals and correlations. Consequently, combining data from several 




Recently, the integration of more complex models instead of basic linear regression 
(as shown in Figure 4) facilitated a new, comprehensive method to investigate the 
regulatory influence of genetic variation on gene expression. Transcriptome wide 
association studies (TWAS) apply a three-step process to identify disease associated 
genes. First, machine learning algorithms, like ridge regression [49], lasso regression 
[50], or elastic net [51], are used to determine a set of genetic variants which 
consistently influence gene expression in a given tissue. Secondly, the corresponding 
set of genetic variants are extracted from classical GWAS datasets and are used to 
predict gene expression based on the generated models. This provides a relative 
expression value per gene for each individual. Finally, predicted gene expression is 
correlated with each individual’s disease status to identify disease-associated genes 
[52–54]. TWAS have several advantages over classical eQTL studies. Due to the fact 
that only thousands of genes are investigated instead of millions of genetic variants, 
less adjustment for multiple testing is required. Additionally, TWAS are an unbiased 
approach as the machine learning model chooses which variants to use for 
reproducible gene expression prediction. Nevertheless, TWAS do also not provide 
information about the biological mechanisms underlying the association signal. 
1.5 Genome editing to investigate gene expression regulation 
Bioinformatical approaches, like GWAS and eQTL studies, are applied to generate 
new hypotheses and to provide a higher-level context. Still, such algorithms cannot 
replace wet lab experiments, which are required to validate findings and to investigate 
biological models under varying conditions. Although the amount of GWAS studies 
rapidly increased in the past 15 years, experimental follow up studies were rarely 
performed [55]. This may in part be attributable to the problematics of interpreting 
GWAS results as described above. Furthermore, investigating specific genetic variants 
required extensive technical effort and often resulted in highly artificial model systems. 
The discovery of the bacterial CRISPR (clustered regularly interspaced short 
palindromic repeats)/Cas9 (CRISPR-associated protein 9) system changed biological 
and medical research dramatically [56–58]. Further developments even simplified the 
multipartite CRISPR/Cas9 complex to require only two components for targeted 
genome editing: The Cas9 endonuclease protein and a single guide RNA (sgRNA) 
(Figure 5 A) [58]. The 20 nucleotide (nt) long sgRNA sequence can be modified to 
induce targeted DNA double-strand breaks (DSBs) via the endonuclease activity of 
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Cas9. sgRNA design further requires the presence of a 3 nt protospacer-adjacent motif 
(PAM) at the 3 prime end of the target sequence.  
 
Figure 5: Cas9 mediated genome editing. 
(A) The Cas9 endonuclease complex requires a sgRNA to introduce targeted double-strand breaks 
(DSBs, red stars). (B) Deactivated Cas9 (dCas9) proteins retain their capability to bind DNA, but lost 
their endonuclease function. The tripartite VPR construct, consisting of the proteins VP64, p65, and Rta, 
was fused to a dCas9 to enable targeted enhancement of nearby gene expression. (Figure modified 
from Wang et al. (2016) [59]) 
Induced DSB are immediately repaired in Eukaryotes by either nonhomologous end 
joining (NHEJ) or homology-directed (HDR) DNA repair pathways. NHEJ usually leads 
to small random insertions or deletions at the DSB targeted site, whereas HDR 
potentially integrates donor DNA sequences by homologous recombination [60–62]. 
Regarding further experimental investigations of GWAS and eQTL results, both 
pathways might be valuable depending on the investigated locus and the specific 
question needed to be addressed. It was further shown that even larger deletions can 
be introduced with the help of two sgRNAs [63,64]. To facilitate additional usage of 
DNA-specific targeting, a nuclease-deactivated Cas9 (dCas9) has been engineered. 
Various effector proteins were fused to dCas9 and have been shown to result in 
targeted transcriptional activation (Figure 5 B) or repression [65,66], and to be capable 
of modifying epigenetics around the target site [67]. 
The CRISPR/Cas9 toolbox has been widely applied to address various questions and 
to generate novel experimental model systems [59]. Still, its implementation, 
specifically concerning the investigation of GWAS loci and eQTL findings, is under 
development. Schrode et al. in 2019 were the first to perform an allelic conversion 
regarding eVariants in vitro [68]. 
1.6 Aim of this study 
The IAMDGC identified 52 independent genetic signals in 34 loci to be involved in AMD 
disease risk [18]. It still remains unclear which variants are indeed causal and exactly 
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which genes in these loci are affected thus contributing to disease pathology. In 
general, a genetic predisposition likely exerts a life-time influence, which leads to the 
question how a genetic variant can contribute to the aetiology of this blinding disease. 
This thesis aims to investigate the influence of AMD-associated genetics in the light of 
gene expression regulation. eQTL databases of various tissues were generated and 
comprehensively analysed. This process especially included the creation and 
evaluation of the first eQTL study in healthy retinal tissue to-date. Besides the large-
scale bioinformatical studies, one project focused on the experimental assessment of 
eQTL effects by applying genome editing methods. Finally, a TWAS was performed 






2 Bioinformatical protocols 
In this thesis, multiple datasets were collected or generated to calculate eQTL in 
various tissues. Table 1 lists all datasets and the respective source. The datasets were 
initially generated using different platforms and methodological protocols. Therefore, 
quality control (QC) and data processing was required to jointly analyse genotype and 
gene expression data. Some datasets were already processed by the respective study 
site before they were made available. The initial data format and the required 
processing steps for eQTL calculation are shown in Table 1. Altogether three 
databases were created in this thesis to investigate gene expression regulation in liver 




Table 1: Overview of analysed eQTL datasets in this thesis 
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reads, QC, Normalisation 
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2.1 Genotype data processing 
2.1.1 Genotype calling 
The genotypes of most investigated datasets were detected using microarray platforms 
and have been made available as hard called genotypes in the VCF format [71] (Table 
1). 
The genotypes of the retinal tissue samples from Regensburg were measured as part 
of this thesis using an Illumina Custom HumanCoreExome BeadChip. Therefore, 
genotype calling was necessary before further genotype processing. Hard called 
genotypes were generated using the Axiome analysis suite version 3.1 based on the 
“best practice workflow” supplied by the manufacturer. 
2.1.2 Quality control before imputation 
Before genotype imputation, every dataset underwent several quality control steps 
regarding the included samples and the genotyped variants. Two datasets, namely 
Schroeder [41] and Innocenti [47], reported only the zygosity status for each variant 
encoded as AA, AB and BB. Biomart [72] was applied to obtain the according reference 
and alternative alleles. Additionally, the UCSC liftover tool [73] was applied to update 
genome coordinates to hg19/GRCh37 if required. 
For each dataset, a principal component analysis (PCA) was carried out including 
30,000 genetic variants of each sample and the corresponding genotype information 
of the 1000 Genomes Project reference panel (Phase 3, release 20130502) [74]. This 
analysis was conducted in R (version 3.3.1) [75] using the snpgdsPCA function of the 
SNPRelate package [76]. The first two principal components were plotted to determine 
the ethnicity of each sample. In this thesis, only samples clustering next to the 
European (EUR) reference individuals were included because haplotype structures 
can importantly vary between populations. Furthermore, samples were excluded in 
case of high missing rates (> 5% of genetic variants) and if reported and inferred 
gender from genotype calling did not match. 
To investigate the quality of genetic variants, allele frequencies were calculated and 
compared to the corresponding allele frequency of the 1000 Genomes Project EUR 
samples. Alleles were flipped, in case they were given on the opposite strand. Genetic 
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variants, whose reference allele frequency deviated more than 10% from the reference 
were excluded from the analysis. Next, VCFtools (version 0.1.15) [71] was applied to 
investigate if variants deviated significantly from Hardy-Weinberg equilibrium (HWE, 
P-value < 1 × 10−6) [77]. Only biallelic autosomal variants were kept for further analysis. 
2.1.3 Genotype imputation 
Before genotype imputation, SHAPEIT2 (version 2.r904) was applied to achieve 
phasing of genotypes with the help of the 1000 Genomes Phase 3 reference panel 
[78]. SHAPEIT2 required a two-step protocol: Initially, the -check option was used to 
identify genetic variants, which did not fulfil the manufacturer’s criteria. These variants 
were thereafter excluded from the phasing process. After genotype phasing, IMPUTE2 
(version 2.3.2) was utilised with standard options to impute genotypes based on the 
previously mentioned reference panel [79]. 
2.1.4 Quality control after imputation 
The genotype imputation produced various output files. These files were converted into 
VCF format with the help of qctools (version 1.2, 
https://www.well.ox.ac.uk/~gav/qctool_v1/#overview accessed February 12th 2017). 
Furthermore, genotypes were converted into the “estimated allele dosage” format. The 
VCF files were filtered for low imputation quality (IMPUTE2 info score) and MAF. The 
Imputation quality threshold for the liver eQTL database was set to 0.4 and the MAF 
was at least 5 %. For all other databases imputation quality threshold was 0.3 with a 
MAF threshold of 1 %. Furthermore, the genomic coordinates of the retina eQTL 
database were lifted to hg38/GRCh38 by applying the UCSC liftover tool. 
2.2 Gene expression data processing 
2.2.1 Microarray data 
The generated eQTL databases in this thesis included three datasets, which measured 
gene expression via microarray (Table 27). Processing of raw data was performed in 
the respective publication [41,47,69].  
The two datasets Schroeder and Innocenti additionally provided the microarray probe 
sequences. Genome annotation changed with time and therefore array probes were 
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remapped to an in silico mRNA reference database from ensembl [80] using the 
ReAnnotator pipeline [81]. After remapping, only exome-matching probes showing less 
than five mismatches were kept. Furthermore, probes which overlapped with a 
common dbSNP variant (version 142) were removed [82]. Only specific probes 
measuring one gene were retained. Probes which unambiguously detected gene 
expression of the same gene, were merged by calculating the mean of all 
corresponding probes. This value was then weighted by the variance of the respective 
single probe over all samples. 
In contrast, Schadt et al. [69] employed the Agilent Custom 44k array and probe 
sequences were not available, which made remapping impossible. The provided gene 
identifier were checked to unanimously match to a gene in the ensemble- or RefSeq- 
[83] database and were excluded from the analysis if this was not the case. 
Furthermore, a Shapiro–Wilk test [84] revealed that values above 2 and below -2 were 
likely outliers and therefore have been set “missing” in the further analysis. 
2.2.2 RNA Sequencing (RNA-Seq) 
All datasets except the ones mentioned in section 2.2.1 used RNA-Seq to measure 
gene expression. For the three studies investigating eQTL in retinal tissue, the raw 
data were available (Table 32) and have been analysed with the same protocol to 
ensure comparability. The RNA-Seq pipeline was based on the protocol of Ratnapriya 
et al. (2019) [70]. During all steps of the analysis, FastQC (version 0.11.5, 
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ accessed January 24th 
2018) and MultiQC (version 1.7.dev0) [85] were applied to ensure the correctness of 
the conducted data processing steps.  
First, the raw RNA-Seq reads were trimmed for Illumina adapter sequences and low 
quality reads were removed with the following options: SLIDING WINDOW 4:5, 
LEADING 5, TRAILING 5, and MINLEN 25 using Trimmomatic (version 0.39) based 
on the supplied Illumina TruSeq3 sequences [86]. Afterwards, the Star aligner (version 
2.7.1a) [87] was applied to build a human reference genome annotation based on the 
ensembl version 97 (GRCh38.p13) [80]. Trimmed reads were aligned to this reference 
using per sample 2-pass mapping and ENCODE standard options. The resulting 
aligned files were thereafter analysed with the RSEM toolbox (version 1.3.1) [88]. To 
accomplish this, a RSEM reference file was created with the rsem-prepare-reference 
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option and the above mentioned ensembl version 97. RSEM then calculated the 
estimated gene expression per sample using the rsem-calculate-expression function 
with standard parameters and the “forward-prob = 0” option to account for stranded 
RNA-Seq libraries. Calculation of gene expression counts required RSEM to assume 
a fragment length distribution, which is done automatically if paired-end reads are 
supplied. The Regensburg dataset investigated retinal gene expression based on 
single-end reads and therefore the options fragment-length-mean 155.9 and fragment-
length-sd 56.2 were additionally supplied to the rsem-calculate-expression function. 
Both values have been obtained by calculating the mean fragment length distribution 
of 30 samples taken randomly from the Cologne and NEI datasets. After gene 
expression calculation, the rsem-generate-data-matrix function created one estimated 
read count matrix per dataset. The estimated expression counts obtained from RSEM 
required further normalisation to enable an appropriate comparison of gene expression 
between samples and datasets. For this reason, the tmmnorm function of the edgeR 
package (version 3.16.5) [89] was applied to conduct a trimmed mean of M-values 
normalisation [90]. The normalised expression matrix was then used by the cpm 
function of edgeR to calculate the gene expression in counts per million (CPM).  
2.2.3 Data normalisation and quality control 
The gene expression matrices of all datasets underwent a uniform data normalisation 
and quality control protocol in R to allow comparison and combination of data. The 
applied protocol was independent of the different RNA measurement methods or units. 
Only expressed genes were kept for data normalisation to remove potential 
measurement artefacts. A gene was considered to be expressed if the expression 
value was at least 1 in 10 % of all samples within the dataset. For the GTEx project 
this threshold was set 0.1 to enable a comparison of results with the original GTEx 
analysis pipeline. Next, a PCA was performed with the help of the prcomp function to 
identify and to remove potential outlier samples within the dataset. Replicated samples 
were merged by taking the mean of the gene expression values. 
The gene expression matrix was then log2-transformed with an offset of 0.001 (liver 
and GTEx eQTL datasets) or 1 (retina eQTL datasets). Thereafter, the single gene 
expression matrices were differently processed according to the three main databases 
created in this thesis, which purposed the calculation of Liver eQTL, the GTEx 
database, or the retina eQTL database. 
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For the calculation of eQTL in liver tissue, only genes were kept which have been 
expressed in at least two of the four datasets. The expression of genes which has not 
been directly measured in all datasets was imputed using the K-Nearest-Neighbour 
method implemented in the impute.knn function of the impute Bioconductor package 
[91]. If imputation was not possible, the gene was removed from further analysis. 
Thereafter, the gene expression matrices of each single dataset were merged into one 
matrix. The log2 transformed and merged matrix was quantile normalised [92] using 
the normalize.quantiles function of the R package preprocessCore 
(https://github.com/bmbolstad/preprocessCore accessed June 16th 2017). As last 
normalisation step, an empirical batch correction method called ComBat was 
performed, which corrected for the different origin of data [93]. The combat function is 
part of the sva package in R [94]. 
The GTEx database was primarily generated based on GTEx v6 (dbGaP: 
phs000424.v6.p1). During the course of this thesis, the GTEx consortium released v7 
(dbGaP: phs000424.v7.p2), which included more samples and tissues. For this reason 
the gene expression data of the GTEx database was processed twice with slightly 
different protocols. In version 6 all samples measuring different tissue subtypes, for 
example “Adipose Subcutaneous” and “Adipose Visceral Omentum”, were merged into 
higher order tissues (e.g. “Adipose”). This resulted in 28 tissues. Thereafter, the gene 
expression quality control and normalisation was conducted for each tissue separately. 
The log2 transformed expression values were quantile normalised and additionally 
rescaled to a mean of 4 (SD: 1) using the rescale function, which is embedded in the 
psych package (https://cran.r-project.org/web/packages/psych/index.html accessed 
June 16th 2017). Rescaling of gene expression ensured a better comparability of effect 
sizes between GTEx tissues. Furthermore, a mega-analysis was conducted based on 
the normalised gene expression matrices of the 28 tissues. For this reason, ComBat 
was applied to adjust for tissue-specific effects by setting the tissue as covariate. The 
updated GTEx database (version 7) applied the same data normalisation protocol like 
version 6 but without merging tissue subtypes. This resulted in 48 different tissues 
being included in the eQTL analysis.  
Three datasets contributed to the retinal eQTL database. Gene expression data were 
merged into one matrix including exclusively genes, which were expressed in all three 
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datasets. Afterwards, quantile normalisation and ComBat were employed to normalise 
the data. 
2.3 eQTL analysis 
2.3.1 eQTL calculation 
In this study, eQTL were calculated based on linear regression models implemented 
in the Matrix eQTL package in R [95]. Matrix eQTL required three input files with 
columns representing samples and rows including the respective data. The files 
contained (1) genotypes in estimated allele dosage format, (2) normalised gene 
expression, and (3) covariates. The covariate file comprised information about age, 
gender, and the first five principal components from the genotype PCA. Furthermore 
the “cisDist” parameter was set to 1 Mbp if local eQTL were investigated. The output 
of Matrix eQTL gave information about several parameters. Besides data about the 
eVariant and the eGene, it presented the effect size (slope of the linear regression 
model, beta), the standard error of the effect size (beta-SE) and the P-value of the 
model. To account for multiple testing, the false discovery rate (FDR, Q-value) was 
calculated using the p.adjust function in R. The results were thereafter filtered for 
significance according to the given Q-value threshold.  
2.3.2 Meta-analysis of eQTL 
The meta-analysis approach compromises the eQTL analysis summary statistics of 
different datasets or tissues and was performed in each database seperately. In this 
thesis, a random effects model implemented in the function MiMa (version 1.4.) [96] 
was applied to conduct a meta-analysis of Matrix eQTL results. It required the beta and 
the beta-SE of each dataset to estimate the joint beta and standard error as well as 
the joint P-value. The retrieved P-values were thereafter corrected for multiple testing 
by applying the FDR. 
2.3.3 Mega-analysis of eQTL and conditional eQTL analysis 
In this study, a mega-analysis was conducted with each of the three generated 
databases. The mega-analysis calculates eQTL from the merged genotype and 
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expression data directly and does not need summary statistics. Matrix eQTL was 
applied after merging the data as described in section 2.3.1. 
Furthermore, the enhanced statistical power of the mega-analysis method was utilised 
to investigate independent eQTL signals for each significant eGene. Matrix eQTL was 
adjusted for the most significant corresponding eVariant per eGene by adding its 
genotype information to the covariate file. Thereafter, eQTL were re-calculated and 
remaining significant eVariants were considered to represent an independent signal. 
The most significant independent eVariant was then also added to the covariate file. 
This approach was repeated until no additional independent signals were found. The 
conditional analysis could not be appropriately adjusted for multiple testing. For this 
reason the P-value threshold for significance of further independent signals was 
estimated based on the applied Q-value threshold of the respective mega-analysis. 
2.4 Transcriptome-wide association study 
The TWAS conducted in this thesis was performed to identify AMD-associated genes 
based on the gene expression regulation of AMD-associated genetic variants. 
Therefore, the PrediXcan algorithm [53] was applied to predict gene expression using 
genotypes of AMD-cases and healthy controls. The required prediction models have 
been trained on the data of European individuals within the GTEx v7 release. Model 
building was performed by Gamazon et al. [53] and the respective files were 
downloaded from PredictDB (http://predictdb.org/, accessed September 3rd 2018). 
Gene expression prediction was accomplished based on the genotypes of 33,976 
unrelated individuals with European ancestry from the IAMDGC cohort [18]. These 
included 16,144 late-stage AMD cases, presenting GA and/or CNV, and 17,832 AMD-
free controls. Genotypes were transformed into allele dosage format and missing 
genotypes of single individuals were replaced by the most frequent corresponding 
genotype. This resulted in 11,722,957 autosomal genetic variants for analysis. Gene 
expression was predicted for 27 tissues and thereafter the lm function was applied in 
R to calculate the linear regression model of gene expression and AMD status, 
encoded as 0 (healthy) and 1 (AMD). The analysis model was further adjusted for 
gender, age and the first two principal components of the genotype PCA performed by 
Fritsche et al. [18]. Multiple testing correction was conducted by calculating the Q-
value. Genes with a Q-value smaller than 0.001 were considered to be significantly 
AMD-associated. Before result evaluation, genes located in the major 
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histocompatibility complex (MHC) locus (chr6: 28,477,797 - 33,448,354, hg19) were 
excluded from the analysis. 
2.5 Follow-up investigations of eVariants and eGenes 
2.5.1 Gene set enrichment analysis with g:Profiler 
Gene set enrichment analysis was performed with the help of the web based tool 
g:Profiler (version r1730_e88_eg35) [97]. The program was used to assign Gene 
Ontology (GO) biological pathways [98] to all query genes and to perform an 
enrichment analysis using the “Best per parent” hierarchical filtering. The g:profiler 
g:SCS method was applied to account for multiple testing and was set to an adjusted 
P-value threshold of 0.05. 
2.5.2 Hierarchical clustering 
Clustering of genes based on their expression was performed using the hclust function 
in R. The hierarchical trees were then processed and visualised with the help of the 
dendextend package [99] in R.  
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3 Material & Methods: Wet lab experiments 
3.1 Material 
3.1.1 Escherichia coli (E. coli) strains 
Table 2: E. coli strains used 
Strain Source 
E. coli strain DH5α Life Technologies, Carlsbad, CA, USA 
E. coli strain Stbl3 Life Technologies, Carlsbad, CA, USA 
3.1.2 Eukaryotic cell lines 
Table 3. Cell lines used and their origin 
Cell Line Organism Tissue of origin Source 
HEK293T Homo sapiens Embryonic kidney 
ATCC, LGC Standards GmbH, 
Wesel, Germany 
3.1.3 Oligonucleotides for PCR and sequencing reactions 
Table 4: Names, sequences and purposes of oligonucleotides used in this thesis 




GAA TTC AAT CAG AGG 
CAA TGG TCT GC 
- 
Cloning of target region for 
UP sgRNA testing, 
Genotyping after ARMS2 
locus deletion 
UP_ARMS2_R_BamHI 
GGA TCC CCT GAT GAA 
TCA TGG TCG AG 
DOWN_ARMS2_F_EcoRI 
GAA TTC TTG ATC ACA 
TGC CAT GCT TTT 
- 
Cloning of target region for 
DOWN sgRNA testing 
DOWN_ARMS2_R_BamHI 
GGA TCC ACG ATA TTT 
TAG GTT GAG GAG CA 
UP_ARMS2_sgRNA_1_F 
CAC CGG ACA CAA GTG 
CTA CAA GGC G 
86 Cloning of UP sgRNA 1 
UP_ARMS2_sgRNA_1_R 
AAA CCG CCT TGT AGC 
ACT TGT GTC C 
UP_ARMS2_sgRNA_2_F 
CAC CGG CCC AGG CCT 
AAT CCA GCG C 
83 Cloning of UP sgRNA 2 
UP_ARMS2_sgRNA_2_R 
AAA CGC GCT GGA TTA 
GGC CTG GGC C 
UP_ARMS2_sgRNA_3_F 
CAC CGA ATT AAC TGA 
GTG CCA GCG C 
83 Cloning of UP sgRNA 3 
UP_ARMS2_sgRNA_3_R 
AAA CGC GCT GGC ACT 
CAG TTA ATT C 
UP_ARMS2_sgRNA_4_F 
CAC CGG CCA GCG CTG 
GAT TAG GCC T 
81 Cloning of UP sgRNA 4 
UP_ARMS2_sgRNA_4_R 
AAA CAG GCC TAA TCC 
AGC GCT GGC C 
UP_ARMS2_sgRNA_5_F 
CAC CGG AGG TGA CAG 
AGC TCT CCG A 
77 Cloning of UP sgRNA 5 
UP_ARMS2_sgRNA_5_R 
AAA CTC GGA GAG CTC 
TGT CAC CTC C 
DOWN_ARMS2_sgRNA_1_F 
CAC CGG ATA CTT AAA 
AGC CAA CCC C 
71 Cloning of DOWN sgRNA 1 
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DOWN_ARMS2_sgRNA_1_R 
AAA CGG GGT TGG CTT 
TTA AGT ATC C 
DOWN_ARMS2_sgRNA_2_F 
CAC CGC ATG CAA CTG 
ATT TAG GGG A 
66 Cloning of DOWN sgRNA 2 
DOWN_ARMS2_sgRNA_2_R 
AAA CTC CCC TAA ATC 
AGT TGC ATG C 
DOWN_ARMS2_sgRNA_3_F 
CAC CGA TGC AAC TGA 
TTT AGG GGA A 
60 Cloning of DOWN sgRNA 3 
DOWN_ARMS2_sgRNA_3_R 
AAA CTT CCC CTA AAT 
CAG TTG CAT C 
DOWN_ARMS2_sgRNA_4_F 
CAC CGT GCA GTT AAT 
GTA ACT CAA T 
71 Cloning of DOWN sgRNA 4 
DOWN_ARMS2_sgRNA_4_R 
AAA CAT TGA GTT ACA 
TTA ACT GCA C 
DOWN_ARMS2_sgRNA_5_F 
CAC CGC ACC TTT GTC 
CTA TTT TGG A 
59 Cloning of DOWN sgRNA 5 
DOWN_ARMS2_sgRNA_5_R 
AAA CTC CAA AAT AGG 
ACA AAG GTG C 
UP_ARMS2_F2 
TTC AGG CCT CCT TCC 
TCA AG 
- 
Genotyping of single 
clones after minimal 
haplotype deletion DOWN_ARMS2_R2 
GGA CAA AGG TGA GGA 
AGT TCA 
YFP-F-AGEI 
ACC GGT ACC ATG GTG 
AGC AAG GGC GAG GA 
- Cloning for px330-GFPo 
YFP-R-ECORI 
GAA TTC TTA CTT GTA 
CAG CTC GTC CA 
MID2_ARMS2_F_EcoRI 
GAA TTC GAC CTC TGT 
TGC CTC CTC TG 
- 
Cloning of target region for 
MID sgRNA testing 
MID2_ARMS2_R_BamHI 
GGA TCC TGA CTC CTC 
TAA CAA CCC GG 
MID_ARMS2_sgRNA_1_F 
CAC CGC CAA CTG GGT 
GGC TTA AAC G 
91 Cloning of MID sgRNA 1 
MID_ARMS2_sgRNA_1_R 
AAA CCG TTT AAG CCA 
CCC AGT TGG C 
MID_ARMS2_sgRNA_2_F 
CAC CGT TCT GTG TAC 
TGA CAC TAT C 
74 Cloning of MID sgRNA 2 
MID_ARMS2_sgRNA_2_R 
AAA CGA TAG TGT CAG 
TAC ACA GAA C 
MID_ARMS2_sgRNA_3_F 
CAC CGC TGA GAC CAC 
CCA ACA ATT C 
81 Cloning of MID sgRNA 3 
MID_ARMS2_sgRNA_3_R 
AAA CGA ATT GTT GGG 
TGG TCT CAG C 
MID_ARMS2_sgRNA_4_F 
CAC CGC GTC ACA CAA 
AAA TGC CCC C 
77 Cloning of MID sgRNA 4 
MID_ARMS2_sgRNA_4_R 
AAA CGG GGG CAT TTT 
TGT GTG ACG C 
MID_ARMS2_sgRNA_5_F 
CAC CGC CTT CCT CTG 
GTT GAA TAG C 
73 Cloning of MID sgRNA 5 
MID_ARMS2_sgRNA_5_R 
AAA CGC TAT TCA ACC 
AGA GGA AGG C 
MID_ARMS2_sgRNA_6_F 
CAC CGG GCC CCT CAA 
GCC GGT GAA T 
90 Cloning of MID sgRNA 6 
MID_ARMS2_sgRNA_6_R 
AAA CAT TCA CCG GCT 
TGA GGG GCC C 
MID_ARMS2_sgRNA_7_F 
CAC CGC TCT GGC AGA 
GCA GGA CTG A 
52 Cloning of MID sgRNA 7 
MID_ARMS2_sgRNA_7_R 
AAA CTC AGT CCT GCT 
CTG CCA GAG C 
MID_ARMS2_sgRNA_8_F 
CAC CGG ATG GCA GCT 
GGC TTG GCA A 
62 Cloning of MID sgRNA 8 
MID_ARMS2_sgRNA_8_R 
AAA CTT GCC AAG CCA 
GCT GCC ATC C 
MID_ARMS2_sgRNA_9_F 
CAC CGC ACT CTG CGA 
GAG TCT GTG C 
69 Cloning of MID sgRNA 9 
MID_ARMS2_sgRNA_9_R 
AAA CGC ACA GAC TCT 
CGC AGA GTG C 
Material & Methods: Wet lab experiments 
28 
MID_ARMS2_sgRNA_10_F 
CAC CGG AAT TGC CTA 
GGC CTC CCT G 
57 Cloning of MID sgRNA 10 
MID_ARMS2_sgRNA_10_R 
AAA CCA GGG AGG CCT 
AGG CAA TTC C 
MID_ARMS2_sgRNA_11_F 
CAC CGA GAT GGC CTT 
CTA TAA GCT T 
78 Cloning of MID sgRNA 11 
MID_ARMS2_sgRNA_11_R 
AAA CAA GCT TAT AGA 
AGG CCA TCT C 
M13F 
CGC CAG GGT TTT CCC 
AGT CAC GAC 
- Vector primer for pGem®-T 
M13R 
AGC GGA TAA CAA TTT 
CAC ACA GGA 
MIAT_sgRNA_1_F 
CAC CGG CGC CCA TGA 
AAT TTT AAT G 
71 Cloning of MIAT sgRNA 1 
MIAT_sgRNA_1_R 
AAA CCA TTA AAA TTT 
CAT GGG CGC C 
MIAT_sgRNA_2_F 
CAC CGA TGC GGG AGG 
CTG AGC GCA C 
74 Cloning of MIAT sgRNA 2 
MIAT_sgRNA_2_R 
AAA CGT GCG CTC AGC 
CTC CCG CAT C 
MIAT_sgRNA_3_F 
CAC CGC ATT AGG CCG 
CAG AGA GCT C 
68 Cloning of MIAT sgRNA 3 
MIAT_sgRNA_3_R 
AAA CGA GCT CTC TGC 
GGC CTA ATG C 
MIAT_sgRNA_4_F 
CAC CGG CTT CTG CGC 
CCC TGG TCC G 
74 Cloning of MIAT sgRNA 4 
MIAT_sgRNA_4_R 
AAA CCG GAC CAG GGG 
CGC AGA AGC C 
* Provided by the Optimized CRISPR Design-Tool (http://crispr.mit.edu, accessed February 1st 2018) 
3.1.4 Oligonucleotides and corresponding probes used for qRT-PCR 
Table 5: Names, sequences and corresponding probe numbers for oligonucleotides used for 
qRT-PCR 
Name 5'-3' Sequence Gene 
Roche Universal 
Probe Library # 
hSDHA-RT-F2 AGC ATC GAA GAG TCA TGC AG 
SDHA 60 
hSDHA-RT-R2 GCT TCC ATC AGC AAA TCT CAA 
huLILRA3_RT_F TGT GTG GTC TCT ACC CAG TGA 
LILRA3 7 
huLILRA3_RT_R CAG AGC CAC ACT GGA AGG TC 
huCD300E_RT_F GGG AGG TGT TGA CCC AAA AT 
CD300E 66 
huCD300E_RT_R AGG ACC ACG AGC AGG AAG T 
huMUC7_RT_F TCA ACT GAC AAG TAG TTT GAC CAG A 
MUC7 69 
huMUC7_RT_R CCA ATC CTT TGA GGA TGG TAA C 
huDEFA5_RT_F TGA GGC TAC AAC CCA GAA GC 
DEFA5 60 
huDEFA5_RT_R GCT CTT GCC TGA GAA CCT GA 
huTNFAIP1_RT_F AGA ACC GGC AAG AAA TCA AG 
TNFAIP1 41 
huTNFAIP1_RT_R CTG GTA GGA GTC CTT CTT GTC C 
huFCN1_RT_F GTT CTG GCT GGG GAA TGA C 
FCN1 38 
huFCN1_RT_R AAC TGG TGG TTG CCC TCA 
huPILRB_RT_F GGT GGA GGA GAA GGA AAG GT 
PILRB 7 
huPILRB_RT_R GGG TCT CAC ATC ACG TCC TC 
huC17orf62_RT_F GCC CTC TCG GGA TGT ACC 
C17orf62 39 
huC17orf62_RT_R TTC CAG CCC AGG CTA TCA 
huDAZAP1_RT_F TCG AGG ACG AAC AAT CAG TG DAZAP1 64 
Material & Methods: Wet lab experiments 
29 
huDAZAP1_RT_R GCT CAG CTC GTT TAA CTT CCA 
huIL6_RT_F GAT GAG TAC AAA AGT CCT GAT CCA 
IL6 40 
huIL6_RT_R CTG CAG CCA CTG GTT CTG T 
huNFKB1_RT_F CCT GGA ACC ACG CCT CTA 
NFKB1 49 
huNFKB1_RT_R TCA TATG GTT TCC CAT TTA ATA TGT C 
huFLOT2_RT_F GAC CCT GGA GGG ACA TCT G 
FLOT2 58 
huFLOT2_RT_R ACT GGT CCC GGT CCT GAT A 
huCYP1A1_RT_F ACC TTC CCT GAT CCT TGT GA 
CYP1A1 33 
huCYP1A1_RT_R GAT CTT GGA GGT GGC TGC T 
hHTRA1-RT-F2 AGC AGA CAT CGC ACT CAT CA 
HTRA1 37 
hHTRA1-RT-R2 GAT GGC GAC CAC GAA CTC 
hMIAT_RT_F AGA ACA CGC TTT ATT ACA GTC TCG 
MIAT 80 
hMIAT_RT_R CCC GAG GTC CAA AGA GAA GT 
hLOC387715-rt-F2 AGC TCT GCT TAC CAG CCT TCT 
ARMS2 82 
hLOC387715-RT-R TTG CTG CAG TGT GGA TGA TAG 
3.1.5 Plasmids and expression constructs 
Table 6: List of expression constructs, short names, applications, and sources 
Vector name Short name Application Source 
pGEM®-T - Cloning 
Promega Corporation, Madison, WI, 
USA 
pCAG-EGxxFP - sgRNA test 












sgRNA vector for 
ARMS2-HTRA1 
haplotype deletion 
Addgene, LGC Standards, 
Teddington, UK 
px330_GFPo px330-GFPo 




Institute of Human Genetics, 




Addgene, LGC Standards, 
Teddington, UK 
3.1.6 Enzymes 
Table 7: Enzymes used 
Enzyme Source 
AgeI New England Biolabs, Ipswich, MA, USA  
BamHI-HF  New England Biolabs, Ipswich, MA, USA  
BpiI New England Biolabs, Ipswich, MA, USA 
EcoRI-HF  New England Biolabs, Ipswich, MA, USA  
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FastDigest Bpil  Thermo Fisher Scientific, Waltham, MA, USA  
GoTaq® DNA Polymerase  Promega Corporation, Madison, WI, USA  
House Taq DNA Polymerase 
Institute of Human Genetics, University of Regensburg, 
Germany 
Quick CIP  New England Biolabs, Ipswich, MA, USA  
RecBCD Exonuclease New England Biolabs, Ipswich, MA, USA  
T4 DNA Ligase  New England Biolabs, Ipswich, MA, USA  
T4 PNK Kinase  New England Biolabs, Ipswich, MA, USA  
Trypsine GE Healthcare, Galfont St Giles, GB  
3.1.7 Kit systems 
Table 8: List of kit systems used 
Kit Source 
BigDye Terminator v1.1, v3.1 Cycle 
Sequencing Kit  
Thermo Fisher Scientific, Waltham, MA, USA  
Lipofectamine 3000 Thermo Fisher Scientific, Waltham, MA, USA 
NucleoSpin® Gel and PCR Clean-up  MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany  
NucleoSpin® Plasmid  MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany  
NucleoBond® XtraMidi  MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany  
Quick Ligation™ Kit New England Biolabs, Ipswich, MA, USA  
3.1.8 Chemicals and cell culture supplements 
Table 9: List of chemicals used 
Chemical/Reagent Source 
Agarose (Biozym LE)  Biozym Scientific GmbH, Hessisch Oldendorf, Germany  
Ampicillin sodium salt Carl Roth GmbH + Co. KG, Karlsruhe, Germany  
Bromphenolblau Natriumsalz  Sigma-Aldrich, St. Louis, MO, USA  
4',6-Diamidin-2-phenylindol (DAPI)  Thermo Fisher Scientific, Waltham, MA, USA  
Chloroquine Merck Chemicals GmbH, Schwalbach, Germany  
DMEM High Glucose Medium (4,5 g/l) Thermo Fisher Scientific, Waltham, MA, USA 
Dimethyl sulfoxide (DMSO) VWR International Germany GmbH, Darmstadt, Germany 
dNTPs (dATP, dGTP, dCTP, dTTP) Genaxxon Bioscience, Ulm, Germany  
Ethanol ≥ 99,8 p.a Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Ethidiumbromide AppliChem GmbH, Darmstadt, Germany  
Ethylendiamintetraacetat disodium 
dihydrate salt (EDTA) 
Merck Chemicals GmbH, Schwalbach, Germany  
Fetal Bovine Serum Gold (FCS) Thermo Fisher Scientific, Waltham, MA, USA 
Glycerol 87 % University of Regensburg, Chemical Supplies 
Gel Loading Dye Purple (6x)  New England Biolabs, Ipswich, MA, USA  
HiDi™ Formamide Thermo Fisher Scientific, Waltham, MA, USA  
Isopropanol  Merck Chemicals GmbH, Schwalbach, Germany  
OptiMEMTM Medium Thermo Fisher Scientific, Waltham, MA, USA 
Penicillin (10.000 Units)/Streptomycin 
(10 mg/ml), (Pen/Strep) 
GE Healthcare, Galfont St Giles, GB  
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Poly-L-Lysine Hydrobromide (0.1 
mg/ml) 
Sigma-Aldrich, St. Louis, MO, USA  
3.1.9 Buffers and solutions 
Table 10: Composition of buffers and solutions used 
Buffer/Solutions Composition and amounts 
5x TBE 
Tris 0,5 M  
Boric acid 0,5 M  
EDTA 10 mM  
H2O dest.  
2x HBS 
NaCl 280 mM  
KCl 10 mM  
Na2HPO4 1.5 mM  
HEPES 50 mM  
H2O dest.  
LB-Medium 
Tryptone 1% w/v 
Yeast extract 0,5% w/v  
NaCL 1% w/v 
H2O dest. 1 l  
LB-Plates 
Tryptone 1% w/v 
Yeast extract 0,5% w/v 
NaCL 1% w/v 
Bacto-Agar 15% w/v 
H2O dest. 1l  
SOC-Medium 
Tryptone 2 % w/v) 
Yeast extract 0,5 % w/v 
NaCl 10 mM 0,5 g/l 
KCl 2,5 mM 0,2 g/l 
Glucose 20mM 20ml 
H2O dest. 1 l 
HEK29T medium 
DMEM High Glucose Medium 89 % 
FCS 10 % 
Pen/Strep 1 % 
HEK29T freezing 
medium 
DMEM High Glucose Medium 70 % 
FCS 20 % 
DMSO 10 % 
3.2 Methods 
In this thesis, a sgRNA mediated CRISPR/Cas9 system was applied to induce DSBs 
or to enhance gene expression. Before these experiments, sgRNAs were tested for 
specificity using a two-vector system. One vector included the sgRNA target sequence 
(pCAG-EGxxFP), whereas the other vector carried the sgRNA- and the Cas9 coding 
sequence (px330-mCherry). Both vectors required different cloning strategies. 
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3.2.1 Cloning of pCAG-EGxxFP constructs 
3.2.1.1 Polymerase chain reaction (PCR) 
The defined sgRNA target sequence was amplified from human genomic DNA 
conducting a Polymerase chain reaction (PCR). The PCR reaction mix is given in 
Table 11 and the respective program in Table 12. PCR conditions were adjusted 
according to primer parameters (given in SnapGene, version 2.8.2) and the required 
elongation time (1 min/1,000 bp). 
Table 11: PCR reaction mix 
Component  Volume  
5x Green GoTaq® Reaction Buffer  5 μl  
Primer forward (10 μM)  1 μl  
Primer reverse (10 μM)  1 μl  
dNTPs (1.25 mM)  2 μl  
human genomic DNA (25 ng/μl)  2 μl  
GoTaq® DNA polymerase 0.1 μl  
H2O (Millipore)  13.9 μl  
 
Table 12: Thermocycler program for PCR amplification 
Step of the reaction Temperature Duration Cycles 
Initial denaturation  95 °C 3 min  
Denaturation  94 °C 30 s 
30 Annealing  x °C* 30 s 
Elongation  72 °C x min 
Final elongation  72 °C 5 min  
Break  4 °C -  
*x indicates variable temperature and time, adjusted for each sequence to be amplified 
3.2.1.2 Agarose gel electrophoresis 
PCR products were run on agarose gels to evaluate amplicon size and purity. Agarose 
gels were generated by heating 1 % (w/v) agarose in TBE buffer until the agarose 
solved completely. After cooling down the mixture to 37°C, 3 drops of 0.003 % 
ethidiumbromide solution were added. If necessary, Bromphenolblue loading buffer 
(5x solution) was added to the samples before loading them onto the gel. 5 μl 
GeneRuler™ DNA Ladder Mix served as a size standard and gels were run at 220 V 
for 20 min. 
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3.2.1.3 Purification of PCR products from agarose gels 
PCR products of the correct size were excised from agarose gels and purified using 
the NucleoSpin® Gel and PCR Clean-up kit according to the manufacturer’s 
instructions. DNA was eluted from columns in 20 μl of Millipore H2O and stored at -20 
°C until further use. 
3.2.1.4 Ligation into pGEM®-T 
The purified PCR amplicons were ligated into the pGEM®-T vector using the ligation 
mix given in Table 13. The ligation reaction was incubated at 4 °C overnight. 
Table 13: pGEM®-T vector ligation mix 
Component  Volume  
pGEM®-T vector  0.5 μl  
PCR fragment  4 μl  
T4 DNA Ligase Puffer (2x)  5 μl  
T4 DNA Ligase  0.5 μl  
3.2.1.5 Heat shock transformation of E. coli 
E. coli cells were transformed with plasmid DNA using a heat shock procedure. One 
100 μl aliquot of competent E. coli cells was thawed on ice for 5 min before half of the 
ligation mixture was added to the cells. The suspension was mixed by flicking the tube 
and then incubated on ice for 30 min. Cells were heat shocked at 42 °C for 40 s and 
placed back on ice for 5 min. 900 μl of SOC medium were added and cells were 
incubated at 37 °C for 1 to 2 h before plating 200 µl of the suspension on LB plates 
containing 100 μg/ml ampicillin. Plates were incubated upside down at 37 °C overnight. 
3.2.1.6 Plasmid DNA miniprep 
Single clones were picked from LB plates and transferred into 5 ml of LB medium 
containing 100 μg/ml ampicillin. After incubation at 37 °C overnight, DNA isolation was 
carried out using the NucleoSpin® Plasmid kit according to the manufacturer’s 
instructions. Plasmid DNA was eluted from columns in 40 μl of Millipore H2O. This 
procedure was repeated by re-pipetting the eluate into the column, followed by 
centrifugation for 1 min (8,000 g). DNA concentration was determined using a 
NanoDrop® ND1000 Spectrophotometer. 
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3.2.1.7 Sanger sequencing 
Sanger sequencing was performed to verify the correctness of clones. For sequencing, 
the BigDye® Terminator v1.1, v3.1 Cycle Sequencing Kit was used. The required 
reaction mix and thermocycler program are given in Table 14 and Table 15. 
Table 14: Reaction mix for Sanger sequencing 
Component  Volume  
Plasmid DNA (20 ng/μl)  2 μl  
BigDye® Terminator Reaction Mix  0.3 μl  
5x BigDye® Terminator Sequencing Buffer  2 μl  
Primer (10 μM)  1 μl  
H2O (Millipore)  4.7 μl  
 
Table 15: Thermocycler program for Sanger sequencing 
Step of the reaction Temperature  Duration  Cycles  
Initial denaturation  94 °C 2 min  
Denaturation  94 °C 30 s 
27 Annealing  58 °C 30 s 
Elongation  60 °C 3 min 
Final elongation  60 °C 5 min  
Break  4 °C -  
 
For DNA precipitation, 5 µl EDTA (125 mM) were added followed by an incubation for 
10 min at room temperature. Next, 50 µl 100 % Ethanol were added and the sample 
was centrifuged for at least 15 min at maximum speed. The supernatant was discarded 
and the sample was washed with 100 µl 70 % Ethanol. After another centrifugation 
step for 7 min, the supernatant was discarded again. Pellets were suspended in 20 μl 
of HiDi™ formamide before analysing them with the help of an Abi3130x1 Genetic 
Analyser. The obtained sequences were evaluated using SnapGene (version 2.8.2). 
3.2.1.8 Restriction digestion 
The verified DNA sequences were transferred from the pGEM®-T vector into the 
pCAG-EGxxFP vector. Therefore, the pGEM®-T vector was digested overnight at 37 
°C using restriction enzymes (Table 16). The digested DNA was run on an agarose 
gel and fragments of correct size were excised and purified as described in 3.2.1.2 and 
3.2.1.3. The DNA fragment was eluted in 20 µl Millipore H2O and DNA concentration 
was determined using a NanoDrop® ND1000 Spectrophotometer. 
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Table 16: Reaction mix for restriction digestion of plasmid DNA 
Component  Volume  
Plasmid DNA  2-3 μg 
Enzyme 1  0.5 μl  
Enzyme 2  0.5 μl  
10x NEB Endonuclease Buffer*  2.5 μl  
H2O (Millipore)  ad. 25 μl  
* Dependent on the enzymes used 
3.2.1.9 Ligation into pCAG-EGxxFP vector 
The insert DNA and the purified digested pCAG-EGxxFP vector were ligated using the 
T4 DNA ligase. The required reaction mix is shown in Table 17. The ligation was 
incubated at 14 °C overnight and thereafter transformed into E. coli. 
Table 17: Reaction mix for ligation of inserts into the pCAG-EGxxFP vector 
Component  Volume  
Digested pCAG-EGxxFP vector 2 μl  
Insert DNA  7 μl  
T4 DNA Ligase Puffer (10x)  2 μl  
T4 DNA Ligase  1 μl  
H2O (Millipore)  ad. 20 μl  
3.2.1.10 Colony PCR 
A colony PCR was conducted to identify positively transformed E.coli clones. First, 
single clones were picked and transferred into 8 µl LB medium containing 100 μg/ml 
ampicillin and incubated at 37 °C for 2 to 4 h. 2 µl of this suspension were used as 
template for a PCR reaction, which was based on the House Taq DNA polymerase 
(Table 18). The applied thermocycler program is shown in Table 12. 
Table 18: Reaction mix for colony PCR 
Component  Volume  
Buffer 10x (15 mM MgCl2) 2.5 μl  
Primer forward (10 μM)  1 μl  
Primer reverse (10 μM)  1 μl  
dNTPs (1.25 mM)  2 μl  
E. coli culture 2 μl  
House Taq DNA polymerase 0.5 μl  
H2O (Millipore)  16 μl  
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3.2.1.11 Plasmid DNA "Midi" preparation 
Cloned constructs were isolated from 100 ml overnight E. coli cultures using the 
NucleoBond® XtraMidi kit according to the manufacturer's protocol. The DNA pellet 
was solved in 100 μl of Millipore H2O. DNA concentration was determined using a 
NanoDrop® ND1000 Spectrophotometer and adjusted to 1 μg/μl. Plasmid DNA was 
stored at -20 °C. 
3.2.1.12 Preparation of glycerol stocks for long term storage 
830 µl of a fresh overnight E. coli culture were mixed with 170 µl sterile 87 % glycerol 
and immediately frozen at -80 °C. Specifications about plasmid constructs were 
entered into the database for glycerol cultures at the Institute of Human Genetics, 
Regensburg. 
3.2.2 Cloning of sgRNAs 
3.2.2.1 Bioinformatical sgRNA design 
The UCSC genome browser [100] was used to obtain the DNA sequence of the 
minimal ARMS2-HTRA1 haplotype, defined by Grassmann et al. (2017) [25]. The 
genome browser marked known genomic repeat regions and showed common variant 
(MAF > 1 %) locations. Next, the Optimized CRISPR Design-Tool (http://crispr.mit.edu, 
accessed February 1st 2018) was applied to identify potential sgRNA candidates and 
to estimate their on-target score. The sgRNA candidates were filtered for the following 
criteria: (1) On-target score of at least 50, (2) sgRNA is located outside a genomic 
repeat region, (3) sgRNA does not overlap a common variant, and (4) no potential off-
targets in known genes. If several sgRNAs fulfilled these thresholds, the genomic 
position was used to manually select candidates. For later cloning processes, two 
oligonucleotides were designed for each sgRNA by adding a “CACCG” sequence to 
the 5 prime end of the forward sgRNA sequence (forward primer) and a “C” nucleotide 
to the 3 prime end of the reverse complement sgRNA sequence (reverse primer). All 
investigated sgRNAs and the respective on-target-scores are shown in Table 4. 
SnapGene (version 2.8.2) was used to visualise and to proof correct sgRNA design. 
Material & Methods: Wet lab experiments 
37 
3.2.2.2 Cloning of sgRNAs into px330 vectors 
All studied sgRNAs were inserted into at least one of the px330 vectors, consisting of 
px330-mCherry, px330-eGFP, and px330-GFPo. This procedure required multiple 
steps and used BpiI restriction sites. 
First, the px330 vector was digested with BpiI for 30 min at 37 °C (Table 19). 
Thereafter, the reaction was purified using agarose gel electrophoresis and the 
NucleoSpin® Gel and PCR Clean-up kit as described in 3.2.1.2 and 3.2.1.3. 
Table 19: Reaction mix for restriction digestion of the px330 vector 
Component  Volume  
px330 vector 1 μg 
BpiI 1 μl  
Quick CIP 1 μl  
10x NEB fast digest buffer  2 μl  
H2O (Millipore)  ad. 20 μl  
 
The two corresponding oligonucleotides for each sgRNA were annealed. This was 
conducted using the reaction mix shown in Table 20. Annealing was performed in a 
Thermocycler, starting with an incubation at 37 °C for 30 min, followed by 95 °C for 5 
min and a step-wise ramp down to 25 °C at 5 °C/min. 
Table 20: Reaction mix for sgRNA oligonucleotide annealing 
Component  Volume  
dATP (10 mM) 1 μl  
Primer forward (100 μM)  1 μl  
Primer reverse (100 μM)  1 μl  
10 x T4 Polynucleotide Kinase Reaction Buffer 1 μl  
T4 PNK 0.5 μl  
H2O (Millipore)  5.5 μl  
 
Next, the digested px330 vector and the annealed sgRNA oligonucleotides were 
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Table 21: Reaction mix for ligation of digested px330 vector and annealed sgRNA 
Component  Volume  
BpiI digested px330 vector 50 ng 
Annealed oligonucleotide duplex (1:200 dilution)  1 μl  
2x Quickligation Buffer (Quick Ligation™ Kit) 5 μl  
Quick ligase (Quick Ligation™ Kit) 1 μl  
H2O (Millipore) ad. 11 µl 
 
The ligation reaction was treated with the RecBCD Exonuclease to prevent unwanted 
recombination products. The respective reaction mix (Table 22) was incubated for 30 
min at 37 °C. 
Table 22: Reaction mix for exonuclease treatment of ligtation reactions 
Component  Volume  
Ligation reaction mix (Table 21) 11 µl 
dATP (10 mM) 1.5 μl  
NEBuffer™ CutSmart® 1.5 μl 
RecBCD Exonuclease 1 μl  
 
After exonuclease treatment, the ligation reaction was transformed into cells of the 
competent E.coli strain Stbl3 as described in 3.2.1.5. Single clones were verified by 
applying Plasmid DNA miniprep and Sanger sequencing, followed by Plasmid DNA 
"Midi" preparation, if required. 
3.2.3 sgRNA efficiency test 
3.2.3.1 Cultivation of HEK293T cells 
Human embryonic kidney (HEK293T) cells were cultivated in 10 cm dishes filled with 
10 ml cultivation medium (Table 10). HEK293T cells were passaged twice a week after 
reaching about 90 % confluency. Old medium was removed and cells were washed off 
the dish with fresh medium. HEK293T cells were seeded into a fresh 10 cm dish at a 
dilution of 1:10. 
3.2.3.2 Transfection of HEK293T cells – calcium phosphate method 
For sgRNA efficiency tests, HEK293T cells were transfected using the calcium 
phosphate method [101]. Cells of a confluent 10 cm dish were diluted 1:14 with 
cultivation medium and seeded on Poly-L-Lysine coated 6-well plates one day before 
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transfection. Each well on the plate contained 3 ml cultivation medium and was 
transfected individually. On the day of transfection, the culture medium was changed 
to HEK293T medium containing 1 μM Chloroquine. After one hour of incubation, the 
medium was changed back to 2.5 ml HEK293T culture medium. The transfection mix 
was prepared according to Table 23 by first mixing DNA with H2O followed by addition 
of CaCl2. Thereafter, 250 µl 2x HBS were added to the tube by gently pipetting on the 
bottom. The resulting two-phases were mixed by gently bubbling air drops into the 
solution.  
Table 23: Transfection mix for calcium phosphate transfection (1 well of 6-well plate) 
Component  Volume  
pCAG-EGxxFP vector carrying the target sequence 1.5 µg 
px330-mCherry vector carrying a sgRNA 1.5 µg 
CaCl2 (2 M) 31 µl 
H2O (Millipore) ad. 250 µl 
 
The mixture was added dropwise to the cells. 7 h after transfection, the medium was 
changed to HEK293T medium and cells were cultivated for another 48 h. The 
transfected cells were then transferred onto a black Poly-L-Lysine coated 96-well plate 
with transparent bottom to enable a standardised fluorescence evaluation. For this 
reason, the cells were detached from the 6-well plate by changing the medium to 1 ml 
of a trypsin solution (1x v/v in PBS). After an incubation step of 5 min at 37 °C, 2 ml of 
HEK293T medium were added. The cell suspension was transferred into a 15 ml falcon 
tube and centrifuged for 3 min at 1000 g. The supernatant was removed and 4 ml fresh 
medium were added to the cells. After gently mixing the suspension, 50 µl were added 
per well on the 96-well plate and thereafter filled up to 100 µl using HEK293T medium. 
The cells were cultivated for another 24 h at 37 °C. 
3.2.3.3 Evaluation of sgRNA efficiency 
72 h after transfection, sgRNA efficiency was analysed by measuring fluorescence 
intensities of transfected cells. Therefore, the culture medium of each well was 
changed to 100 µl 1 x PBS and the whole plate was transferred into a FLUOstar 
OPTIMA plate reader. Two fluorescence spectra were recorded: (1) eGFP (excitation: 
488 nm, Emission 509 nm) to detect sgRNA efficiency, and (2) mCherry (excitation: 
587 nm, Emission 610 nm) to evaluate transfection efficiency. eGFP raw fluorescence 
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counts were normalised for transfection efficiency and thereafter compared to cells, 
which were transfected using only pCAG-EGxxFP without px330-mCherry. 
Additionally, fluorescence images were taken for documentation purposes concerning 
the above mentioned channels. 
3.2.4 Deletion of the minimal haplotype in the ARMS2-HTRA1 locus 
The CRIPSR/Cas9 system can be applied to induce large genomic deletions. 
Therefore, two sgRNAs flanking the target region have to be transfected in combination 
with a Cas9 expression cassette. 
3.2.4.1 Transfection of HEK293T cells with Lipofectamine 
HEK293T cells were transfected with a combination of one px330-eGFP vector 
carrying the first sgRNA, which targets the upstream region of the minimal haplotype, 
and one px330-mCherry vector targeting the downstream region. Lipofectamine 3000 
was used according to the manufacturer’s protocol for 6-well plates and 1.5 µg of each 
vector were included in the reaction. 
3.2.4.2 FACS sorting and single-cell cultivation 
72 h after transfection with Lipofectamine 3000, HEK293T cells were transferred into 
a 15 ml falcon tube as described in 3.2.3.2 and underwent “Fluorescence activated cell 
sorting” (FACS). FACS was applied to filter for living cells, which showed an eGFP-, 
and mCherry fluorescence. Cells, which fulfilled these criteria were transferred onto 
one well of a Poly-L-Lysine coated 6-well plate and incubated until confluency. During 
that incubation, half of the medium was exchanged every second day gently by not 
detaching the cells from the plate. After the transfected cells reached 100 % 
confluency, one half of the cells was transferred into a new well for further cultivation 
and the other half was frozen at -80 °C for long term storage using HEK29T freezing 
medium. 
48 h later, the cells were detached from the plate and counted using the CASY TT 
system. The cells were then diluted in HEK293T cultivation media to an approximate 
concentration of one cell in 40 µl. 40 µl of this dilution were transferred into one well of 
a Poly-L-Lysine coated 96-well plate until the whole plate was occupied. The cells were 
then monitored daily to ensure that exclusively one cell colony arose per well, 
Material & Methods: Wet lab experiments 
41 
otherwise the well was excluded from further analysis. During monitoring, the medium 
was changed weekly until single clones reached 100 % confluence. Thereafter, cells 
were split 1:3 on two wells of a six well plate, one for isolation of genomic DNA (gDNA) 
and one for RNA extraction. The remaining cells were frozen. 
3.2.4.3 gDNA isolation 
gDNA of HEK293T cells was isolated following the protocol from Lairds et al. (1991) 
[102].  
3.2.5 Measuring gene expression 
3.2.5.1 RNA isolation 
RNA isolation from mammalian cells was conducted using the Qiagen RNeasy Mini Kit 
according to the manufacturer’s instructions. RNA was eluted two times in 50 µl 
RNase-free water and RNA concentration was determined using a NanoDrop® 
ND1000 Spectrophotometer. The RNA was stored at -20 °C for short term and at -80 
°C for long term use. 
3.2.5.2 cDNA synthesis 
For complementary DNA (cDNA) synthesis, 1µg of RNA was diluted in 12.5 µl RNase-
free H2O and mixed with 1 μl of poly(dT) primer (30 nmol). The mixture was then heated 
to 70 °C for 5 min and thereafter the cDNA synthesis reaction mix (Table 24) was 
added. This reaction was incubated in a thermocycler for 10 min at 25 °C, followed by 
42 °C for 1 h and a final step of 70 °C for 15 min. 
Table 24: Composition of cDNA synthesis reaction mix 
Component  Volume  
5x Reaction Buffer for RevertAid™ Reverse 
Transcriptase 
4 µl 
dNTPs (1.25 mM) 2 µl 
RevertAid™ Reverse Transcriptase 0.5 µl 
 
After cDNA synthesis, 30 µl RNase-free H2O were added to the reaction volume to 
dilute the cDNA for further applications. The cDNA was stored at 8 °C for short term 
use and at -20 °C for long term storage. 
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3.2.5.3 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) was performed with primers based on the 
“Universal Probe Library” by Hoffmann-La Roche. The qRT-PCR experiments were 
conducted in triplicates on 384-well plates using the QuantStudio™ 5 Real-Time PCR 
System. The reaction mix and the PCR conditions are given in Table 25 and Table 26. 
Table 25: Reaction mix for qRT-PCR analysis 
Component  Volume  
cDNA (20 ng/μl) 2.5 µl 
2x TaqMan Gene Expression Master Mix 5 µl 
Primer forward (10 μM) 1 µl 
Primer reverse (10 μM) 1 µl 
Probe 0.125 μl 
H2O (Millipore) 0.375 μl 
 
Table 26: qRT-PCR conditions 
Step of the reaction Temperature Duration Cycles 
Denaturation  95 °C 40 s  
Annealing  60 °C 60 s  
Elongation  72 °C 2 min 40 
 
The data were analysed using the ΔΔCt-approach and gene expression levels were 
normalised in regard to the housekeeper gene “succinate dehydrogenase complex 
flavoprotein subunit A” (SDHA). 
3.2.6 Targeted enhancement of gene expression 
Targeted enhancement of gene expression was performed with the help of the dCas9-
VPR vector generated by Chavez et al. (2015) [66]. This approach required two 
expression constructs: (1) the sgRNA expression cassette and (2) the dCas9-VPR 
encoding construct. An alternative px330 vector was generated, because the px330 
vector family carries the Cas9 expression cassette, which is impedimental for gene 
expression enhancement. Therefore, the px330-GFPo was created by cutting out the 
Cas9 expression cassette of a px330-eGFP vector using the restriction enzymes 
EcoRI-HF and AgeI. The cloning procedure followed the protocols described in 3.2.1. 
To enhance gene expression, a double-transfection of the px330-GFPo vector 
including a sgRNA and the dCas9-VPR vector was required. This was performed in 
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HEK293T cells using Lipofectamine 3000 as described in 3.2.4.1. 72 h after 





4.1 A mega-analysis of eQTL in liver tissue 
The first project explored the regulatory landscape of gene expression in liver tissue to 
understand functional consequences of genetic variants associated with complex 
diseases. In addition, this project should provide the basis for further eQTL studies by 
elaborating a detailed data analysis protocol. For this reason, publicly available data 
from four independent studies (Table 27) were collected. Each of these studies 
calculated eQTL in liver tissue and evaluated the results regarding different aspects. 
In this thesis, the studies were named after their first author in the case of (1) Schadt 
et al. [69], (2) Schroeder et al. [41], and (3) Innocenti et al. [47] or the respective 
consortium in case of (4) GTEx v6 [44]. Overall, genotype and gene expression data 
of a total of 588 individuals were included in the analysis. 
Table 27: Study overview of datasets combined in the liver eQTL database 






178 149 178 83 
Origin of liver 
tissue 
Post-mortem tissue 




surgery for liver 
cancer 
Post-mortem tissue 
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QC = quality control; * GTEx v6 includes two data releases: Start and Mid, which used partially different 
platforms: Omni 2.5M for the first data release (GTEx start) and Omni 5M for the mid-point release 
(GTEx mid). ** After quality control, the genotype files of the four studies were merged into a single file 
and variants, which did not overlap between datasets, were assigned as missing. Variants had to be 
genotyped in at least 100 samples or were excluded. 
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The investigated liver eQTL studies used different genotyping and expression profiling 
platforms (Table 27), which demanded a stringent QC to jointly analyse the data. The 
QC was applied to all included individuals, genotyped variants, and the measured gene 
expression. A detailed overview of all QC steps is provided in the Bioinformatical 
protocols section. Briefly, only individuals of European descent with low missing rates 
of genotype and gene expression data were included. The QC of genotyped variants 
filtered for variants: (1) measured in all datasets, (2) with allele frequencies comparable 
to the 1000 Genomes Project reference panel, (3) located on autosomes, (4) with MAF 
above 5 %, and (5) no significant deviation from HWE. This procedure resulted in 
861,575 variants for imputation. The gene expression data underwent a separate QC 
depending on the data source. 24,123 genes, which were measured in at least two 
datasets were considered for further data processing. 
4.1.1 Elaboration of a data-normalisation protocol 
Each of the four studies used distinct platforms and data processing protocols, which 
required a normalisation pipeline. Normalisation was necessary for genotype and gene 
expression data. The different genotype files were combined and imputed using the 
same reference panel. This enabled the analysis of 6,256,941 shared genetic variants. 
The gene expression data underwent different processing protocols before joint 
analysis because three studies used microarray platforms, whereas the GTEx data 
were based on RNA-Seq (Table 27). Therefore, gene expression values were merged 
into one matrix and log2 transformed to evaluate potential cofounder effects by PCA. 
This analysis showed that samples of the same dataset clustered together and that the 




Figure 6: Gene expression data normalisation process. 
A PCA was conducted on the merged gene expression data of the four datasets (GTEx, Innocenti, 
Schadt, Schroeder), at three different consecutive normalisation steps: (A) raw log2 transformed merged 
data (no normalisation), (B) quantile normalised data and (C) after adjustment for known batch effects 
using ComBat. In addition, the gene expression values are presented as boxplots at the same stages 
(D-F). (Figure published in Strunz et al., 2018 [103]) 
Next, quantile normalisation (QN) was performed to adjust gene expression values in 
regard to their scale. After QN, the datasets Schroeder, Innocenti, and GTEx 
converged regarding principal component (PC) 1. In addition, gene expression value 
ranges showed comparable median values and variability (Figure 6 B and E). Since 
QN alone was not sufficient to normalize all studies, an empirical batch correction 
method called ComBat [93] was applied. After these normalisation steps, clustering of 
individuals with regard to their original dataset was not apparent to any further extent 
(Figure 6 C and F). 
4.1.2 Analysis of local eQTL 
eQTL calculation was first performed for each of the four studies separately using a 
linear regression model, which was adjusted for several covariates and included one 
gene and one variant at a time. Only local eQTL were considered for further analysis 
by investigating a window of 1 Mbp up- and downstream of the transcription start site 
or polyadenylation site of a gene locus. Next, mixed effects models were applied to 
perform a meta-analysis based on the effect sizes and standard errors of each study. 
These models estimated one joint effect size, standard error and a combined P-value 
for each eQTL. All P-values were adjusted for multiple testing by calculation of the FDR 
[104] and Q-values smaller than 0.001 were considered statistically significant. At this 
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threshold, 101,148 eVariants and 1,313 genes regulated by eQTL were identified 
(Table 28). Remarkably, only 38.5 % (see GTEx Start/Mid) to 60.9 % (see Innocenti) 








   
Schadt Schroeder Innocenti GTEx Start/Mid Meta-Analysis Mega-Analysis 
Q-value  
< 0.05 
eQTL  73,999 165,518 122,474 54,639 222,521 444,276 
eVariants (unique) 68,636 154,799 114,635 49,176 205,942 383,213 
eGenes (unique) 1,592 3,453 2,635 1,983 4,811 7,612 
Overlapping eGenes 
Meta-analysis 
802 (50.38 %) 1,578 (45.7 %) 1,379 (52.33 %) 661 (33.33 %) 4,811 (100 %) 4,486 (58.93 %) 
Overlapping eGenes 
Mega-analysis 
1,100 (69.1 %) 2,168 (62.79 %) 1,805 (68.5 %) 1,023 (51.59 %) 4,486 (93.24 %) 7,612 (100 %) 
Q-value  
< 0.001 
eQTL  29,546 71,423 52,565 19,802 101,148 202,489 
eVariants (unique) 27,689 69,292 49,594 16,953 95,257 183,872 
eGenes (unique) 363 913 670 387 1,313 1,959 
Overlapping eGenes 
Meta-analysis 
215 (59.23 %) 491 (53.78 %) 408 (60.9 %) 149 (38.5 %) 1,313 (100 %) 1,260 (64.32 %) 
Overlapping eGenes 
Mega-analysis 
288 (79.34 %) 688 (75.36 %) 537 (80.15 %) 207 (53.49 %) 1,260 (95.96 %) 1,959 (100 %) 
P-value  
< 1 x 10-6 













Data preparation and QC of the four datasets further allowed to jointly analyse the 
merged genotype and gene expression data by calculation of eQTL in the entire 
database. This mega-analysis is known to have a higher statistical power in 
comparison to the classical meta-analysis approach [48,105]. The mega-analysis 
yielded 202,489 statistically significant eVariants affecting the expression of 1,959 
genes (Q-value < 0.001). Compared to the results from the meta-analysis, the mega-
analysis provided a two-fold increase in the number of eVariants and a 1.5-fold 
increase in the number of differentially regulated genes. Both, mega- and meta-
analysis discovered more significant results than any of the four individual studies 
alone. Furthermore, the overlap of single study results and the mega-analysis is on 
average 19 % higher (53.5 to 80.15 %) than the overlap observed with the meta-
analysis (Table 28). Because of these observations, all further evaluations were based 
on the mega-analysis results. Moreover, the mega-analysis enabled the detection of 
independent eVariants using a conditional eQTL analysis. Therefore, the eQTL 
analysis was repeated for each significant eGene after additionally adjusting the linear 
regression model for the most significant eVariant identified for the respective gene. P-
values lower than 1.00 x 10-6 were considered significant (corresponding to a Q-value 
of 0.001 in the primary mega-analysis). The procedure was repeated until no further 
significant independent eVariants were found. With this approach, 101 additional 
independent eVariants regulating 93 of the 1,959 liver eGenes were identified. 
Interestingly, several independent signals would have not been considered significant 
(Q-value < 0.001) in the primary mega-analysis (Figure 7). 
 
Figure 7: Manhattan plot of the eQTL mega-analysis in liver. 
A mega-analysis was conducted including 588 samples of four independent studies detecing eVariants 
in liver tissue. The Manhattan plot shows the −log10 Q-values of the most significant eVariant for each 
of the 24,123 analysed autosomal genes. Additionally, 101 independent secondary signals were 
identified and are highlighted in red. The blue line depicts the threshold for significance 1.00 x 10-3. 
(Figure published in Strunz et al., 2018 [103]) 
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4.1.3 Characterisation of eVariants in liver tissue 
 
The liver eQTL results were further evaluated to better understand potential molecular 
mechanisms. First, the most significant eVariant and independent signals for each 
eGene were plotted in regard to their genomic position (Figure 8). 
Figure 8: Characterisation of 
independent eVariants based on their 
genomic localisation. 
The distance to the transcription start site 
(TSS, red line) is plotted against the -
log10 P-values of the most significant 
eVariant for the respective eGene, 
including secondary signals 
(independent hits). Negative/positive 
distances denote that the variant is 
located upstream/downstream of the 
TSS in regard to the direction of 
transcription. (Figure published in Strunz 
et al., 2018 [103]) 
 
Most of the significant eVariants were located close to the respective TSS. Altogether, 
1,599 out of 2,060 independent eVariants were located within 100,000 base pairs 
around the TSS. Nevertheless, 55 eVariants were located more than 500 kbp away 
from the regulated eGene. 
In a next step, eVariants were further characterised in regard to known DNA features 
and regulatory elements by searching RegulomeDB [106]. This database applies a 
seven-level functional scoring system to grade genetic variants. Category one variants 
affect very likely transcription factor binding and alter gene expression, whereas 
category 7 variants lack evidence for any functional relevance. Altogether, three 
groups of variants from the liver eQTL database were evaluated: (1) all unique 
significant eVariants of the mega-analysis (N = 183,872), (2) the most significant 
eVariant per eGene and the independent signals (N = 2,060), and (3) a random set of 
200,000 genetic variants within 1 Mbp of a gene locus, which served as “control” 
(Figure 9 A). Remarkably, the first set including all eVariants was enriched in 
RegulomeDB classes one to four (P-values < 6.82 × 10−09). In addition, the second set 
of independent signals revealed an even stronger enrichment in classes one to four 
compared to controls and compared to all eVariants (P-values from 1.72 × 10−04 to 




Figure 9: Functional annotations and predicted consequences of local eVariants. 
Three sets of variants were evaluated by employing two different databases. Set one (mega-analysis) 
consists of all significant mega-analysis eVariants (Q-Value < 0.001) while the second group comprises 
the most significant eVariant and the independent hits for each eGene. Set three (control) includes 
random variants of the imputed genotype file, which are located next to at least one gene within a 
distance of a maximum of 1 Mbp. (A) The chart depicts the percentage of variants per variant set 
categorised into seven groups by RegulomeDB. The seven-level functional score is based on a 
synthesis of data derived from various sources: category 1 variants are very likely to affect transcription 
factor binding and are linked to gene expression of a target gene (i.e. are known eVariants); categories 
2 and 3 are likely to affect at least transcription factor binding and several other regulatory effects; 
categories 4-6 show minimal functional indication while category 7 variants lack evidence for any 
functional relevance.(B) The chart shows the percentage of variants classified into ten classes of 
consequences according to the Ensembl Variant Effect Predictor (VEP). For variant set one (mega-
analysis) and two (independent hits), only the predicted consequence affecting the identified eGene was 
included. For the control group, one random gene within a variant–gene distance of a maximum of 1 
Mbp was chosen. If the variant had different effects on transcripts of the same gene, the most severe 
effect was selected. *** P-value for difference between groups < 0.001. (Figure published in Strunz et 
al., 2018 [103]) 
Besides characterisation of eVariants in regard to transcription factor binding and gene 
regulation, another database was used to analyse potential molecular mechanisms 
based on gene structure and variant position. The ensembl variant effect predictor 
(VEP) [107] rates variants in regard to all surrounding transcripts and classifies them 
according to potential functional consequences. Control variants were predominantly 
located upstream (49.22 %) and downstream (49.09 %) of known gene structures. 
Another 1.63 % of the control variants were found in introns of genes. Less than 0.1 % 
of the control variants were assigned to functional categories such as missense or 
untranslated transcript region (UTR). Interestingly, the proportion of intronic variants 
was significantly larger in both, the mega-analysis variants (19.72 %, P < 1.00 × 10−150) 
and the independent hit variants (29.17 %, P < 1.00 × 10−150) (Figure 9 B). Additionally, 
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other predicted categories like UTR or coding region variants occurred more often (P-
values < 1.72 × 10−07). 
Taken together, these findings indicate that significant eVariants are more often 
localised within known gene structures and are likely regulatory variants as they are 
found within regions of transcription factor binding and open chromatin. This is 
especially the case for the most significant eVariants and independent secondary 
signals. 
4.1.4 Liver eQTL of AMD-associated variants 
The liver eQTL database was further used to identify molecular mechanisms, which 
might be relevant for AMD aetiology. For this reason, the 52 independent AMD-
associated variants identified by Fritsche et al. (2016) [18] were investigated in regard 
to gene expression regulation in liver. 31 of these 52 variants were successfully 
genotyped or imputed in the liver eQTL database and showed an allele frequency > 5 
%. Interestingly, 8 of these variants were associated with gene expression of 15 unique 
eGenes (Q-value < 0.05, Table 29).  
Table 29: Liver eVariants overlapping with genome-wide significant AMD-associated variants 
CHR: chromosome; SE: standard error of the effect size; * IH: Independent hit according to Fritsche et 
al. (2016) [18] ** Effect size of a single AMD risk increasing allele 













1.2 rs570618 1 196,657,064 CFHR1 4.34E-10 0.711 0.099 G T 
1.1 rs10922109 1 196,704,632 CFHR4 1.66E-21 1.118 0.105 A C 
1.1 rs10922109 1 196,704,632 CFHR1 2.54E-21 0.992 0.094 A C 
1.1 rs10922109 1 196,704,632 CFHR3 2.11E-14 0.923 0.107 A C 
1.1 rs10922109 1 196,704,632 F13B 0.012 0.216 0.057 A C 
1.1 rs10922109 1 196,704,632 CFH 0.025 0.338 0.095 A C 
1.6 rs61818925 1 196,815,450 CFHR3 1.55E-06 0.649 0.113 G T 
1.6 rs61818925 1 196,815,450 CFHR1 0.006 0.416 0.103 G T 
1.6 rs61818925 1 196,815,450 CFHR5 0.011 -0.371 0.096 G T 
11 rs7803454 7 99,991,548 PILRB 5.72E-24 0.251 0.022 C T 
11 rs7803454 7 99,991,548 PILRA 1.04E-08 0.372 0.056 C T 
23.1 rs2043085 15 58,680,954 ALDH1A2 0.016 0.207 0.056 T C 
23.2 rs2070895 15 58,723,939 LIPC 6.88E-07 0.561 0.095 A G 
23.2 rs2070895 15 58,723,939 ADAM10 0.021 -0.217 0.06 A G 
24.2 rs17231506 16 56,994,528 CETP 0.008 -0.216 0.055 C T 
27 rs6565597 17 79,526,821 TSPAN10 2.46E-07 -0.526 0.086 C T 
27 rs6565597 17 79,526,821 ACTG1 0.016 0.312 0.084 C T 
27 rs6565597 17 79,526,821 ANAPC11 0.036 -0.171 0.05 C T 
Results 
53 
Several of the AMD-associated variants are located in the CFH locus (IH 1) and 
influence gene expression of CFH and CFHR genes. Particularly, the independent hit 
variant rs10922109 (independent hit 1.1 in Fritsche et al. 2016 [18]) tags a common 
deletion of CFHR1/CFHR3. Since the deletion of both genes is protective against AMD, 
the risk increasing allele results in an elevated expression of the two genes, which is 
represented by the respective effect sizes in Table 29 (rs10922109 - CFHR1: 0.992 
and rs10922109 - CFHR3: 0.923). Besides the CFH locus, two other eGenes are well 
known in AMD-related research: LIPC and CETP. Both genes are be involved in HDL 
metabolism and are specifically well characterised in liver tissue.  
4.2 Investigation of local eQTL in the GTEx project 
Several studies showed that regulation of gene expression is a tissue dependent 
process [108,109]. The GTEx project measured genotype and gene expression data 
of various tissues from more than 600 donor individuals. These data were composed 
using clearly defined sample collection criteria and sample processing steps [44,46]. 
Furthermore, the GTEx consortium initially performed the tissue-specific analysis of 
local eQTL and made a curation of their significant results accessible online. 
Nevertheless, not all of the results are available through their online repository. For this 
reason, one objective of this thesis was to download the raw data of the GTEx project 
and to create an openly accessible in-house database at the Institute of Human 
Genetics Regensburg. This database was generated based on the data processing 
protocol of the above presented eQTL analysis in liver tissue. The in-house GTEx 
database was created with GTEx version 6 (v6) and later updated to GTEx version 7 
(v7), which included additional samples and used whole genome sequencing instead 
of genotyping microarrays. Supplementary Table 1 summarises the information for 
the 48 tissues of GTEx v7, which were integrated and analysed. The sample size 
varied from 72 (see “Brain substantia nigra” and “Minor salivary gland”) to 418 (see 
“Muscle skeletal”) with a mean sample size of 183.6 (SD 94.4) across all tissues. The 
mean number of expressed genes per tissue was 29,591.9 (SD 3,065.9) (Figure 10). 
Remarkably, in testis (sample size: 197) 42,810 genes were expressed, which equates 




Figure 10: Expressed genes and eGenes of GTEx v7. 
GTEx v7 compromises gene expression, genotype, and covariate data of 48 different tissues and cell types. Local eQTL were calculated for each tissue seperately 
and adjusted for multiple testing (Q-value). The barplot visualises the number of expressed genes per tissue and the identified eGenes using two significance 
thresholds: Q-value < 0.05 (grey) and Q-value < 0.001 (black). The sample size for each tissue (n) is given in brackets. 
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The number of eGenes varied widely from 19.4 % (5,741 of 29,667 genes, see “Small 
intestine terminal ileum”) to 57.17 % (19,890 of 34,789 genes, see “Thyroid”) of all 
expressed genes in the respective tissue (Q-value < 0.05). A linear regression model 
showed that the number of expressed genes significantly (P-value: 0.000315, R2: 
0.23) correlates with the sample size per tissue (Figure 11 A). Remarkably, another 
analysis revealed an almost linear relationship (P-value: 2.38 x 10-19) with an R2 of 
0.83 between the tissue-specific sample size and the number of detected eQTL 
(Figure 11 B). 
 
Figure 11: Correlation of sample size and tissue-specific paramters of GTEx v7. 
A linear regression model was used to investigate the correlation of the tissue-specific sample size with 
the respective number of (A) expressed genes and (B) eQTL (Q-value < 0.05). The regression line is 
depicted in blue and the regression coefficent (R2) for each model is shown in the bottom right corner. 
Altogether, the in-house GTEx database included eQTL data regarding 48 tissues and 
was created as a basis to enable further projects outside the scope of this thesis. These 
projects included for example the calculation of combinatory effects regarding AMD-
associated eVariants and the evaluation of potential pleiotropic effects of eVariants. 
4.3 Distant eQTL in the ARMS2-HTRA1 locus 
4.3.1 Distant eQTL calculation 
Processing of the GTEx database enabled various further projects besides the 
calculation of local eQTL. One of these projects aimed at elucidating potential distant 
eQTL effects of AMD-associated variants and focused on the ARMS2-HTRA1 locus at 
10q26. This locus showed the most significant AMD-association in the European 
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population (P-value 6.5 x 10−735) and the highest OR (2.81) of all 34 loci identified by 
Fritsche et al. (2016) [18]. The low P-values and the high LD in the ARMS2-HTRA1 
locus (Figure 2 B) initially hindered detailed statistical investigations. Finally, a 
haplotype analysis of Grassmann et al. (2017) [25] refined the AMD-associated signal 
to a region of 5,196 bp (chr10:124,210,369-124,215,565, hg19), called the “minimal 
haplotype”. Additionally, the locus contains two variants, which are known to locally 
regulate the gene expression of ARMS2 through different mechanisms. rs3750846, 
the lead variant of the study from Fritsche et al. (2016) [18], co-localises with a deletion 
of the ARMS2 gene. The other variant, rs2736911 results in a truncated ARMS2 
protein (R38X). Interestingly, rs2736911 was not found to be associated with AMD [22].  
To investigate potential regulatory mechanisms, local and distant eQTL were 
investigated for the ARMS2-HTRA1 locus in all GTEx v6 tissues, since GTEx v7 was 
initially not available. After the eQTL calculation, a meta-analysis jointly evaluated 
single tissue results. In this analysis, both variants regulate the expression of ARMS2 
(Q-values: rs3750846 1.5 x 10-09, rs2736911 2.8 x 10-31). Altogether the expression of 
1,098 respectively 1,120 eGenes was significantly (Q-value < 0.05) associated with 
rs3750846 or rs2736911. To identify different regulatory effects, the gene lists were 
filtered to exclude (1) genes regulated by both variants, (2) genes, which expression 
was correlated with ARMS2 expression, and (3) genes involved in housekeeping 
processes. Housekeeping genes were identified by sorting out genes matching the GO 
processes including the phrases: “ribonucleo” and “metaboli”. Filtering was performed 
to identify the potentially AMD-associated mechanism separated from the shared 
regulation of ARMS2. Interestingly, a gene enrichment analysis showed that the gene 
list of rs3750846 included mainly immune system related genes, whereas rs2736911 









Table 30: Ten most significant gene enrichment analysis results of eGenes associated with 
rs3750846 or rs2736911 
rs3750846 (922 genes) rs2736911 (962 genes) 











52 6.69E-05 Cell cycle 152 7.06E-11 
Myeloid leukocyte activation 59 1.38E-04 Organelle organisation 262 2.71E-09 
Myeloid cell activation 
involved in immune 
response 
53 2.69E-04 Cilium assembly 44 6.33E-06 
Neutrophil degranulation 49 4.67E-04 Ciliary basal body docking 21 1.59E-05 
Response to stress 228 5.48E-04 
Antigen processing and 
presentation of exogenous 
antigen 
28 4.83E-05 
Multi-organism process 159 1.22E-03 
Negative regulation of ubiquitin-
protein transferase activity 
17 8.53E-04 
Translational elongation 20 2.08E-02 Cell division 55 3.26E-03 
Acute inflammatory 
response 
19 3.51E-02 Intracellular transport 135 3.99E-03 
Response to biotic stimulus 68 3.99E-02 Chromosome segregation 37 6.87E-03 
Protein folding 26 4.10E-02 
Protein deneddylation  




Taken together, rs3750846 regulates 922 genes, which expression showed no 
association with the non AMD-associated variant rs2736911, and which were enriched 
for immune system related processes. To further narrow down this gene list, a mega-
analysis including all GTEx v6 tissues was conducted based on the merged and 
normalised gene expression files. Furthermore, the mega-analysis was adjusted for 
tissue donors because some individuals donated multiple organs. After filtering for 
significant eGenes (Q-value < 0.01), which were not involved in housekeeping 
processes, rs3750846 regulated the expression of 455 genes. Again, ARMS2 revealed 
the most significant result (Q-value 3.7 x 10-12). The mega-analysis approach facilitated 
to conduct a conditional analysis, which was adjusted for the expression of the most 
significant gene and was repeated until none of the primary significant signals (round 
0) remained. Interestingly, the adjustment for ARMS2 expression (round 1) did not 
affect the significance of any other eGene (Figure 12). The most significant gene after 
adjustment for ARMS2 was CD300E (Q-value 1.3 x 10-12), which is known to participate 
in innate immune response [111–113]. Adjustment for CD300E resulted in 114, mostly 
immune related, genes losing significance (arrow, Figure 12). The subsequent 
adjustments for XKR9 and KLHDC4 altered the list of eGenes only marginally, whereas 





Figure 12: Conditional mega-analysis of rs3750846-associated eGenes in GTEx v6. 
Gene expression and genotype files from all GTEx v6 tissues were merged to conduct a mega-analysis regarding rs3750846. The eQTL analysis resulted in 455 
genes which were clustered based on their gene expression using the hclust function in R and are shown as dendrogram (top). The bar below the dendrogram 
visualises if a gene is known to participate in immune system processes (“Immune gene”, turquoise). After the primary analysis (round 0), the eQTL calculation 
was adjusted for the most significant gene and repeated as long as at least one eGene reached significance (Q-value < 0.01, bars from top to bottom). Genes, 
which lost significance turn black in this schematic figure. The three colors red, green, and blue mark if an adjustment led to noticable changes in the list of significant 





After the conditional mega analysis, the hypothesis emerged suggesting that the strong 
AMD-association of rs3750846 could be caused by distant effects on gene expression, 
which are shared by various tissues and cell types. Several parameter were chosen to 
further evaluate rs3750846-associated eGenes and to finally test the hypothesis in 
vitro. The eGenes were categorised for (1) high absolute effect sizes (> 0.05) in the 
mega-analysis and (2) for regulation by local eVariants (Q-value < 0.05). If this was the 
case, the respective local eVariants were explored in the AMD GWAS data as given in 
Fritsche et al. (2016) [18] for their AMD-association (Q-value < 0.05). This procedure 
was applied to validate the potential relevance of the eGene in the context of AMD. 
Furthermore, the eGenes of interest were queried for immune-related GO terms, and 
if they were shown to be expressed in HEK293T cells. These criteria resulted in 13 
potential candidate genes, which fulfilled most aspects (Table 31).  
Table 31: Manually curated list of potential rs3750846 target genes for experimental validation 
Symbol 
Strong effect of 
rs3750846 in mega-
analysis (ABS > 0.05)* Local AMD-associated eVariants**  Immune related 
Expressed in 
HEK293T*** 
C17orf62 - (-0.01) + - + 
CD300E + (-0.065) - + + 
CYP1A1 + (0.093) - - + 
DAZAP1 - (-0.006) + - + 
DEFA5 + (-0.091) + + + 
FCN1 - (-0.045) + + + 
FLOT2 - (-0.011) + - + 
IL6 + (-0.063) - + + 
LILRA3 + (-0.1) + + NA 
MUC7 + (-0.127) + + + 
NFKB1 - (-0.007) + + + 
PILRB - (0.011) + + NA 
TNFAIP1 - (-0.011) + + + 
* Effect size of the AMD risk increasing allele, ** Fritsche et al. (2016) [18] Q-value < 0.05 (calculated 
over all GWAS variants), *** Mean expression of untreated HEK293T cells of three studies [114–116]; 
NA = gene was not measured or not detected 
4.3.2 Genome editing to delete the minimal haplotype in HEK293T cells 
After bioinformatical analysis of the 10q26 locus, an experimental approach was chosen 
to evaluate the hypothesis regarding distant regulatory mechanisms of AMD-associated 
variants located in the minimal haplotype region. The experiments were designed to 
experimentally manipulate the ARMS2-HTRA1 locus using the CRIPSR/Cas9 system 




Figure 13: Scaled overview of the genomic region flanking the minimal haplotype. 
Grassmann et al. (2017) [25] performed an haplotype analysis of the ARMS2-HTRA1 locus and 
identified a 5,196 bp (chr10:124,210,369-124,215,565, hg19) genomic region, which most likely 
harbours the variants causative for the GWAS signal. Several sgRNAs (orange) were designed 
upstream (UP), within (MID), and downstream (DOWN) of the minimal haplotype region. After sgRNA 
specificity testing, six sgRNAs (blue) were chosen for further experiments. No sgRNAs were designed 
to target the genomic repeat region (red), because these might also bind to other regions in the genome. 
The figure shows the genomic region chr10:124,209,369-124,216,565 and was scaled to correctly 
present the positions of all shown elements. 
sgRNAs were created to recruit the Cas9 endonuclease and to introduce DSBs at the 
ARMS2-HTRA1 locus. Subsequent recombination events are expected to result in a 
deletion of all or parts of the minimal haplotype region. Five sgRNAs were bioinformatically 
designed to bind up- (UP) or downstream (DOWN) of the minimal haplotype. These 
sgRNAs were tested for specificity using the pCAG-EGxxFP system established by 
Mashiko et al. (2013) [118] (Figure 14 A). The pCAG-EGxxFP vector contains an EGFP 
expression cassette, which is interrupted by the sgRNA target sequence. If the sgRNA 
specifically binds its target, the Cas9 endonuclease is recruited and introduces a DSB. The 
subsequent recombination event restores the EGFP cassette and leads to a fluorescence 
signal, which can be detected via microscopy. The number of positively transfected cells 
showing green fluorescence serves as quantitative marker for sgRNA specificity. Figure 
14 B presents a representative set of experiments included in the testing of 5 UP sgRNAs. 
These were separately cloned into the px330-mCherry vector and transfected into 







Figure 14: Specificty test of UP sgRNAs. 
(A) Schematic overview of the vector set required for the sgRNA specificty test. The px330-mCherry 
vector carries one sgRNA- (blue) and a Cas9 (grey) expression cassette follwed by a mCherry 
enconding sequence (red). The pCAG-EGxxFP construct carries an EGFP expression cassette (green) 
interrupted by the respective sgRNA target sequence (blue). (B) Exemplary set of experiments to test 
the efficiency of five sgRNAs located upstream (UP) of the minimal haplotype defined by Grassmann et 
al. (2017) [25]. Each sgRNA was cloned into the px330-mCherry vector and double transfected in 
combination with the corresponding pCAG-EGxxFP construct. Green flourescence represents sgRNA 
specificity, whereas red flourescence marks the transfection efficency of px330-mCherry. (C) 
Quantitative evaluation of three independent UP sgRNA tests using the FLUOstar OPTIMA plate reader. 
Measurement values were normalised to the green background flourescence of the pCAG-EGxxFP 
vector (top left in B) and to the mean transfection efficency (red flourescense) per experiment. 
After quantitative evaluation of sgRNA specificity, two sgRNAs upstream (UP sgRNA 
2 and 3, Figure 14 C) and downstream (DOWN sgRNA 1 and 2) were chosen for the 
targeted deletion of the minimal haplotype (Figure 13). Therefore, a combination of 
one UP (px330-eGFP vector) and one DOWN sgRNA (px330-mCherry vector) was 
transfected into HEK293T cells. After an incubation time of 72h, FACS sorting was 
performed to identify cells positively transfected with both constructs. Then, single cells 
were isolated using a dilution series and seeded onto new plates with a statistical 
dilution of one cell per well. Two PCR reactions targeting the minimal haplotype region 
(Figure 15 A) enabled the identification of introduced genomic alterations. Altogether, 
18 single clones homozygous for the deletion were identified (Figure 15 B). Additional 
18 clones did not show any recombination events and served as controls, since they 





Figure 15: Genotyping and qRT-PCR of HEK239T cells edited in the ARMS2-HTRA1 locus. 
(A) Two PCRs were conducted to genotype HEK293T single clones after genome editing with one 
sgRNA binding upstream and one sgRNA binding downstream the minimal haplotype region. The 
regions covered by PCR 1 and 2 are visualised by the black lines above the annotation. The elongation 
time for both PCRs was 1 min, which is too short to amplify the full minimal haplotype region with PCR 
1. Therefore, no amplicon of PCR 1 indicates that no deletion occured. (B) Genoytpe PCR results of 
seven representative single clones. The zygosity state was determined based on the results of PCR 1 
and 2 and is given as: Homozygous for minimal haplotype deletion (D), hemizygous (H), or wild type 
(WT). The PCRs were replicated indedpently for at least two times to validate genotyping results. (C) 
qRT-PCR results regarding 6 exemplary target genes (Table 31). Shown are the mean values of 7 WT 
clones and 8 deletion clones. The results were normalised in regard to the respective WT clones 
qRT-PCRs regarding the potential target genes (C17orf62, CD300E, CYP1A1, 
DAZAP1, DEFA5, FCN1, FLOT2, IL6, LILRA3, MUC7, NFKB1, PILRB, and TNFAIP1) 
of the ARMS2-HTRA1 locus did not reveal any significant differences in gene 
expression despite the deletion of the minimal haplotype region (Figure 15 C). It is 
important to note that no implications about the potential effect direction are possible 
because eQTL results were based on the AMD risk allele (Table 31) but in this 
approach the whole minimal haplotype region was deleted. 
4.3.3 Enhancing gene expression in the minimal haplotype region 
Besides the deletion of the minimal haplotype region, a further approach aimed to 
enhance its potential influence on gene expressing regulation. Therefore, a protocol 
published by Chavez et al. (2015) [66] was employed. The workgroup generated the 
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tripartite activator “VP64-p65-Rta” (VPR), which was fused to a dCas9. Using this 
construct, targeted enhancement of gene expression is possible without changing the 
natural chromosomal context. To establish the VPR method at the Institute of Human 
Genetics Regensburg, the findings of Chavez et al. (2015) were first replicated by 
targeting the gene MIAT with a mixture of the same sgRNAs as published by Chavez 
et al. (2015). Remarkably, gene expression of MIAT was enhanced by a fold change 
of 113.4 (SD: 14.3) in comparison to a transfection of HEK293T cells, which did not 
include the MIAT sgRNAs (Figure 16 A). 
 
Figure 16: Enhancement of gene expression using dCas9-VPR in HEK293T cells. 
(A) qRT-PCR results after double transfection of HEK293T cells (n = 3) with a mixture of four MIAT 
sgRNAs published by Chavez et al. (2015) [66] and the dCas9-VPR vector. (B) Targeted enhancement 
of gene expression within the ARMS2-HTRA1 locus was performed with the help of the two sgRNAs 
MID 8 (n = 6) and MID9 (n = 4). qRT-PCR results of five exemplary bioinfomatically predicted target 
genes (Table 31) and HTRA1 are shown. qRT-PCRs were normalised in regard to dCas9-VPR 
transfected HEK293T cells (control, n = 7) without supplying any sgRNA. 
Eleven sgRNAs (MID sgRNA 1 to 11) were tested for efficiency following the protocol 
described above and the two sgRNAs MID 8 and 9 (Figure 13) were chosen for 
targeted enhancement of the ARMS2-HTRA1 minimal haplotype region. Nevertheless, 
qRT-PCRs of the bioinformatically predicted target genes did not show any significant 
changes in gene expression of dCas9-VPR and MID sgRNA transfected cells in 
comparison with control cells (Figure 16 B). The usage of sgRNAs UP 2, UP 3, DOWN 
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1, and DOWN 2 in combination with dCas9-VPR failed also to reveal an altered 
expression of target genes. 
4.4 RNA sequencing and eQTL analysis of retinal tissue 
4.4.1 Study overview of the retinal eQTL database 
The liver eQTL database and GTEx did not include eye tissue, which would be a 
valuable resource for the investigation of ocular diseases and traits. To date, only a 
single study calculated eQTL in retina, but included over 300 AMD patient eyes in their 
dataset of a total of 406 samples. Therefore, one aim of the current thesis was to 
analyse gene expression regulation in 161 healthy retinal samples collected at the 
Institute of Human Genetics Regensburg. Furthermore, two other collaboration 
partners, namely the University Hospital in Cologne and the National Eye Institute 
(NEI), shared their raw RNA-Seq and genotype data to enable an eQTL mega-analysis 
of healthy retinae. The data processing and QC was performed similar to the mega-
analysis in liver tissue. After QC, 314 samples were available for further analysis 
























Sample size before QC/ after QC 161 / 144 78 / 76 105 / 94 
Mean Age 59.2 (SD: 16.8) 
70.1 (SD: 
12.6) 
74.2 (SD: 9.4) 

















RNA-Seq platform Illumina HiSeq platform 
RNA-Seq depth 20 m SE 50 - 80 m PE 10 - 20m PE 
Read length 83 bp 51 bp 125 bp 
Expressed genes (CPM > 1 in 10 % of 
samples) 
18,290 18,971 18,401 










ank v1.0 chip 
Imputed variants after QC 8,686,883 
eVariants (Q-value < 0.05) 869,464 
eVariants (Q-value < 0.05, unique) 600,077 
eVariants regulating several Genes (Q-value 
< 0.05) 
149,078 
eGenes (Q-value <0.05, unique) 9,733 
Independent signals (P-value < 4.0 x 10-4) 15,262 
eVariants (Q-value < 0.001) 426,461 
eVariants (Q-value < 0.001, unique) 305,268 
eVariants regulating several Genes (Q-value 
< 0.001) 
69,116 
eGenes (Q-value <0.001, unique) 2,757 
Independent signals (P-value < 3.9 x 10-6) 3,082 
PE = Paired-end; QC = quality control; SD = standard deviation; SE = Single-end 
RNA-Seq reads were initially analysed separately per individual dataset. A total of 
2,412 genes were found to be exclusively expressed (CPM > 1 in at least 10 % of the 
samples) in only one or two of the three datasets and were subsequently excluded. 
This left information on a total of 17,405 genes shared between the three datasets 
which were combined and normalised together. Regarding the genotype data, each 
dataset was separately imputed, which resulted in 8,686,883 overlapping and quality-
controlled variants (Table 32). 
The merged genotype- and gene expression data were then explored for local eQTL. 
Local eQTL were calculated by including all variants on the same chromosome that 
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are located within 1 Mbp up- or downstream of the TSS or polyadenylation site of the 
respective gene. After adjustment for multiple testing, 869,464 significant eVariants (Q-
value < 0.05) were identified, which regulate 9,733 unique eGenes (Table 32). 
Moreover, a conditional analysis revealed 5,529 additional independent (secondary) 
signals by adjusting for the respective most significant primary eVariant (P-value < 4.0 
x 10-4). A more stringent adjustment for multiple testing (Q-value < 0.001) resulted in 
2,757 unique eGenes and 325 secondary signals (P-value < 3.9 x 10-6). 
4.4.2 Characterisation of gene expression regulation in retina 
The primary and secondary signal eVariants were first characterised with respect to 
their significance and position regarding the corresponding eGenes (Q-value < 0.05) 
(Figure 17 A). Signals were widely distributed around the TSSs of the respective 
eGenes. Interestingly, highly significant eVariants were observed to be located closer 
to the TSS in comparison to less significant eVariants. Nevertheless, some eVariants 
were located several thousand bp away from the respective TSS and showed highly 
significant P-values. This was especially the case for the eQTL rs577360216 - 
MAPK8IP1P2 (P-value: 5.59 x 10-117, TSS distance: +668,829 bp) and rs6075340 - 
SIRPB1 (P-value: 5.17 x 10-96, TSS distance: +293,628 bp). 
 
Figure 17: Genomic localisation of eVariants in the retinal eQTL database. 
(A) The distance of each eVariant to the TSS of the respective eGene is plotted against the significance 
of the association (−log10 P-value). Shown are the primary (dark grey) and independent secondary, 
(light grey) eVariants for each eGene. Negative/positive distances denote that the variant is located 
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upstream/downstream of the TSS with regard to the direction of transcription. (B) Boxplot of the absolute 
distance of primary and secondary signals to the TSS. Significance was assessed by a Mann-Whitney-
U-Test (P-value = 4.2 x 10-104). (Figure modified from Strunz et al., 2020 [119]; Note that the shown 
figure differs from the publication because the data preparation protocol changed during manuscript 
revision. Details are given in the respective method sections.) 
Interestingly, more than half (8,488/15,262) of the independent signals were located 
downstream of the respective TSSs. Furthermore, primary signals were found to be 
located significantly closer to the TSS in comparison with secondary signals (Figure 
17 B, P-value = 4.2 x 10-104).  
149,078 (24.8 %) of the 600,077 unique eVariants (Q-value < 0.05) regulated the 
expression of more than one eGene. Therefore, the question arose if these highly 
regulatory active variants are distributed randomly over the genome or if they cluster 
in so called “regulatory clusters”. To answer this question, the list of eVariants was 
filtered for (1) a Q-value of 0.001 (305,268 eVariants, Table 32) and (2) eVariants 
regulating at least three genes, resulting in 25,299 variants for further analysis. 
Thereafter, variants, which were located close to each other (1 Mbp window) were 
assigned to the same cluster. This analysis revealed 76 regulatory clusters, which are 
distributed over the whole genome (mean number of clusters per chromosome: 3.45, 
SD: 2.39) (Figure 18). Remarkably, chromosome 7 harbours most clusters (9 of 76), 
whereas no clusters were found on chromosome 4 and chromosome 13. The cluster 
size varied widely from 1 bp (clusters 5:122982802-122982802, 10:79629844-
79629844, 11:7885630-7885630, 11:49154505-49154505, 16:19584627-19584627), 
each containing a single eVariant regulating several eGenes to 6,433,565 bp for cluster 




Figure 18: Chromosomal position of regulatory clusters in retinal tissue. 
Highly significant eVariants regulating three or more eGenes (Q-Value < 0.001) were combined into 76 
regulatory clusters (orange) and mapped onto the human genome (window size 1 Mbp). The plot was 
generated by using the chromoMap package in R [120]. 
4.4.3 Retinal eQTL and AMD-associated genetic variants 
The 52 AMD-associated IHs identified in the AMD GWAS of Fritsche et al. (2016) [18] 
were investigated in the retinal eQTL database. 41 of these were genotyped or imputed 
into the dataset and 7 variants regulate the expression of at least one eGene (Q-value 
< 0.05) (Table 33). Altogether, 13 unique eGenes were regulated by AMD-associated 
variants. 
Table 33: Genome-wide significant AMD-associated variants regulating genes in retinal tissue 











8.3 rs204993 6 32,187,804 HLA-DQB1 1.54E-05 -0.484 0.086 A G 
8.3 rs204993 6 32,187,804 TSBP1-AS1 1.85E-04 0.190 0.037 A G 
11 rs7803454 7 100,393,925 PILRA 4.50E-51 0.850 0.044 C T 
11 rs7803454 7 100,393,925 PILRB 7.29E-27 0.785 0.061 C T 
11 rs7803454 7 100,393,925 STAG3L5P 1.83E-23 0.557 0.047 C T 
11 rs7803454 7 100,393,925 ZCWPW1 3.93E-03 0.155 0.036 C T 
18 rs3750846 10 122,456,049 BX842242.1 5.22E-10 0.204 0.027 T C 
19 rs3138141 12 55,721,994 AC009779.3 1.91E-03 -0.170 0.037 C A 
24.1 rs5817082 16 56,963,437 MT3 1.52E-02 -0.273 0.069 CA C 
24.1 rs5817082 16 56,963,437 RSPRY1 2.63E-02 0.082 0.022 CA C 
24.1 rs5817082 16 56,963,437 GNAO1 3.00E-02 -0.129 0.034 CA C 
26 rs11080055 17 28,322,698 TMEM199 1.28E-02 0.069 0.017 A C 
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27 rs6565597 17 81,559,795 ARL16 3.96E-02 0.101 0.028 C T 
CHR: chromosome; SE: standard error of the effect size; * IH: Independent hit according to Fritsche et 
al. 2016 [18] ** Effect size of a single AMD risk increasing allele 
4.4.4 Investigation of GWAS variants with regard to different ocular traits 
The retina eQTL database facilitates not only the analysis of gene expression 
regulation in the context of AMD, but may be applied to address various other related 
questions. Christina Kiel, a researcher at the Institute of Human Genetics, generated 
a curated list of variants associated with at least one of 82 different traits and diseases 
(at genome-wide significance, P-value < 5.0 x 10-8) [121]. The data collection also 
included variants regarding 12 distinct ocular traits and diseases derived from 16 
published GWAS (Table 34). 
Table 34: Complex eye diseases and traits investigated in the context of retina eQTL 
(data kindly provided by Christina Kiel, Institute of Human Genetics, Regensburg [121]) 













Age-related macular degeneration 26691988 52 41 7 13 











251 243 32 47 
Macular thickness 30535121 135 129 29 45 
Myopia 23468642 22 22 3 3 
Optic disc - cup area 28073927 24 23 2 2 
Optic disc - disc area 28073927 16 16 4 4 
Primary angle closure glaucoma 27064256 8 7 1 2 
Primary open-angled glaucoma 
26752265, 
29891935 




119 98 14 21 
Vertical cup-disc ratio 28073927 22 21 1 1 
QC = quality control 
The number of GWAS variants varied widely from 3 (see “diabetic retinopathy”) to 251 
(see “intraocular pressure”). Overall, 690 variants were included in the retinal eQTL 
database and 100 of these showed an association with at least one eGene (Q-value < 
0.05). 125 unique eGenes were identified, since some disease- or trait-associated 
eVariants regulate multiple genes. Remarkably, 17 of these eGenes are regulated by 
eVariants associated with multiple different phenotypes (Figure 19). For example, 
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lower expression of the non-annotated protein coding gene AC009779.3 is potentially 
associated with increased risk for AMD, refractive error, and increased macular 
thickness while decreased gene expression of AC009779.3 is associated with an 
increased risk of myopia. Furthermore, AMD-associated variants were also found to 
upregulate the expression of PILRA, which expression change is also potentially linked 
to macular thickness, and to downregulate HLA-DQB1, which is downregulated by 
intraocular pressure-associated variants. 
 
Figure 19: Retinal eGenes regulated by multiple complex eye disease- or trait-associated 
variants. 
17 eGenes (orange) were regulated by genome-wide significant GWAS variants of at least two different 
complex eye diseases or traits (blue). Connective lines are colored according to the eQTL effect 
direction of the risk-/trait- increasing allele. Red lines reflect higher gene expression whereas blue lines 
represent downregulation of expression. AMD = age-related macular degeneration; CCT = central 
corneal thickness; IOP = intraocular pressure; MT = macular thickness; MYP = myopia; ODCA = optic 
disc - cup area; ODDA = optic disc - disc area; PACG = primary angle closure glaucoma; POAG = 
primary open-angled glaucoma; RE = refractive error. (Figure modified from Strunz et al., 2020 [119]; 
Note that the shown figure differs from the publication because the data preparation protocol changed 
during manuscript revision. Details are given in the respective method sections) 
4.5 TWAS based on AMD genetics and the GTEx project 
eQTL analyses are based on linear regression models and usually consider one 
genetic variant and one gene at a time. Gamazon et al. (2015) proposed a more 
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complex model, which uses classical machine learning approaches and called it 
PrediXcan [53]. This algorithm is applied to determine a set of genetic variants which 
consistently influence gene expression in a given tissue. In a second step, these 
variants can be extracted from a GWAS dataset to predict the relative gene expression 
of study participants. Finally, the imputed gene expression is correlated to the 
individuals’ disease status to identify disease-associated genes. The three step 
procedure is called TWAS and can be applied to identify genetically regulated genes, 
which are potentially relevant for disease aetiology. 
4.5.1 Identification of 106 genes associated with AMD 
The PrediXcan algorithm [53] was applied to the full IAMDGC dataset [18], which 
includes genotype and phenotype data from 16,144 late-stage AMD cases (including 
clinical diagnoses of GA and/or CNV), and from 17,832 AMD-free controls. The 
prediction models from 27 tissues were retrieved from PredictDB (http://predictdb.org/, 
accessed September 3rd 2018) and were implemented into the analysis. These tissues 
have been chosen because genotype and gene expression data of more than 130 
individuals were available for prediction model building. After separate gene 
expression imputation for each tissue, a linear regression model was applied to identify 
late-stage AMD-associated genes based on the individual’s AMD status. P-values 
were adjusted for multiple testing using the FDR approach and genes with a Q-value 
smaller than 0.001 were considered to be significantly associated with AMD. In each 
tissue, a minimum of 11 (see “Brain Cerebellum” and “Heart Left Ventricle”) and up to 
28 (see “Adipose Subcutaneous” and “Nerve Tibial”) AMD-associated genes (Figure 
20) were identified (mean 17.63; SD 5.02). Altogether, 106 unique genes were 




Figure 20: TWAS results for 27 tissues. 
A TWAS was conducted based on the genotypes of 16,144 late-stage AMD cases and 17,832 AMD-
free controls. Prediction models of 27 tissues were included in the analysis. The schematic overview 
demonstrates the number of significant AMD-associated genes (Q-value < 0.001) within the respective 
tissue. If a gene was found exclusively in a single tissue, it was marked as tissue-specific (TS). Tissue 
classification was performed manually according to main functions or metabolic assignments. Adipose 
SU: Adipose Subcutaneous; Adipose VO: Adipose Visceral Omentum; Artery AO: Artery Aorta; Artery 
TI: Artery Tibial; Brain CE: Brain Cerebellum; Breast MT: Breast Mammary Tissue; Cells TF: Cells 
Transformed fibroblasts; Colon SI: Colon Sigmoid; Colon TR: Colon Transverse; Esophagus GJ: 
Esophagus Gastroesophageal Junction; Esophagus MC: Esophagus Mucosa; Esophagus MS: 
Esophagus Muscularis; Heart AA: Heart Atrial Appendage; Heart LV: Heart Left Ventricle; Muscle SK: 
Muscle Skeletal; Nerve TI: Nerve Tibial; Skin NSS: Skin Not Sun Exposed Suprapubic; Skin SEL: Skin 
Sun Exposed Lower leg. (Figure published in Strunz et al., 2020 [122]) 
Of 106 AMD-associated genes, 88 are located in loci known to be AMD-associated 
with genome-wide significance. 18 additional genes were not located in proximity 
(window size of 1MB) to any of the 52 independent hits identified by Fritsche et al. 
(2016), and may denote novel AMD loci [18] (Figure 21). The linear regression models 
also provide an effect size based on the regression slope (beta). Positive effect sizes 
point to predicted gene expression in healthy tissue being higher in AMD cases than 
controls. Negative betas are suggestive for decreased gene expression with higher 
AMD risk. The largest effect sizes ranged from -0.38 (ARMS2, see “Testis”) to +0.35 
(CFHR1, see “Liver”) (Supplementary Table 2). The mean absolute beta across all 




Figure 21: Manhattan plot of the AMD-associated genes in all 27 investigated tissues. 
Linear regression models were performed to correlate the predicted gene expression of 27 tissues with 
AMD and control status. The Manhattan plot shows the −log10 Q-values and the chromosomal position 
for all predictable genes. Genes, which were significantly AMD-associated (Q-Value < 0.001; red line) 
in at least one tissue were highlighted in blue, if the gene was located in a known AMD locus, or green 
if the locus was not genome-wide significant in the GWAS of Fritsche et al. (2016) [18]. (Figure published 
in Strunz et al., 2020 [122]) 
Interestingly 54 out of the 106 genes were significantly AMD-associated in more than 
one of the 27 tissues (Figure 20 and Supplementary Table 2). Remarkably, sixteen 
genes (ADAM19, ARMS2, BTBD16, CFH, CFHR1, CFHR3, GPR108, PILRA, PILRB, 
PLA2G12A, PLEKHA1, PMS2P1, PPIL3, RDH5, STAG3L5P, and TNFRSF10A) were 
AMD-associated in over 10 tissues. Furthermore, some genes showed an AMD 
association of predicted gene expression in almost all analysed tissues. This is 
especially the case for three genes (PILRA, PILRB, and STAG3L5P) located within the 
known AMD Locus 11 [18]. 
4.5.2 Comparison to AMD TWAS of retinal tissue 
The study of Ratnapriya et al. (2019) included a TWAS analysis based on retinal eQTL 
data and the summary statistics of the AMD GWAS from Fritsche et al. (2016) [18,70]. 
The TWAS comprised data of 406 retinae, which were mainly derived from AMD 
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patients. Altogether, the TWAS identified 31 significantly AMD-associated genes (Q-
value < 0.001, genetic model R2 ≥ 0.01) of which 22 were located outside the MHC 
locus. These genes were compared to the PrediXcan analysis regarding the 27 GTEx 
tissues to identify potential retinal-specific effects. 16 of the 22 genes were also found 
to be AMD-associated in at least one of the 27 GTEx tissues and are therefore unlikely 
to represent retinal-specific effects. Remarkably, only two genes showed different 
effect directions in the retinal tissue TWAS compared with other GTEx tissues. One of 
these genes was HTRA1, of which the retinal expression was predicted significantly 
lower in AMD cases than controls. This was also true for the two tissues “Esophagus 
Mucosa” and “Esophagus Gastroesophageal Junction”. In contrast, predicted HTRA1 
expression was significantly higher in AMD cases than controls in five GTEx tissues 
(see “Thyroid”, “Skin Sun Exposed Lower leg”, “Heart Atrial Appendage”, “Pituitary”, 
and “Testis”). On the other hand, the predicted retinal expression of PLA2G12A, 
located on chromosome 4, was lower in AMD cases compared to controls. The 
opposite effect direction was observed in all 13 GTEx tissues in which predicted 
PLA2G12A expression was significantly associated with AMD status.  
Two of the remaining six genes, exclusively found by Ratnapriya et al. (2019), were 
not measured in the GTEx dataset: the long non-coding RNA STAG3L5P-PVRIG2P-
PILRB and the uncharacterised gene RP11-644F5.10 (ENSG00000258311). 
Therefore, no conclusions can be drawn. The remaining four genes are expressed in 
several GTEx tissues, but were not AMD-associated in any of the 27 tissues 
investigated. Two out of these four genes are the uncharacterised transcripts PARP12 
and CTA-228A9.3. Finally, the remaining two genes are the protein coding genes 
MEPCE and RLBP1. The latter encodes the retinaldehyde-binding protein 1, which 





Publically available GWAS data reveal a plethora of loci and variants which are 
genome-wide associated with complex diseases and traits. For a number of reasons, 
functional interpretation of disease-associated genetic variants remains challenging 
and requires large scale approaches to avoid missing the potential small effects. Most 
of the GWAS genetic variants are located in non-coding regions of the genome and 
are common in healthy individuals [33]. Additionally, the extensive LD often hinders 
the identification of the signal causing variant or the respective gene. Therefore, 
investigation of gene expression regulation enables to combine statistical methods with 
the analysis of molecular data. This lays the foundation to generate new hypotheses 
regarding causal genes in GWAS loci and potentially disease relevant pathways. 
Three databases regarding gene expression regulation were generated in this doctoral 
thesis. First, four different studies investigating gene expression in liver tissue were 
processed and combined to enable an eQTL mega-analysis. According to the 
established data processing protocol, gene expression and genotype data of the GTEx 
project were prepared to build an in-house database, which includes data of 48 
different tissues and cells. This database was helpful to support ongoing projects at 
the Institute of Human Genetics and to generate new hypotheses. In a further project, 
an eQTL database including 314 retinal tissue samples from three independent study 
sites was generated and analysed in regard to multiple complex phenotypes. The large 
datasets were established to enable new insight into the aetiology of AMD, a complex 
eye disease with a strong genetic background. Besides the identification of gene 
regulatory functions within AMD-associated loci, a new hypothesis regarding the 
ARMS2-HTRA1 locus was generated and evaluated experimentally using genome 
editing via the CRISPR/Cas9 technology. In a final project of this thesis, machine 
learning was applied to allow an unbiased investigation into AMD genetics. This 
analysis resulted in a list of 106 AMD-associated genes potentially involved in various 
molecular pathways throughout the whole body. 
The analysis of gene expression in single tissues revealed that many genes are 
genetically regulated and that the number of eGenes varies between tissues and 
databases. For example, 31.6 % of all expressed genes in the liver eQTL database 
were eGenes (7,612 of 24,123), whereas in the retinal eQTL database this was the 
case for 55.9 % (9,733 of 17,405).  
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A more detailed investigation of the liver eQTL database revealed that single studies 
showed remarkably less eGenes in comparison to the combined analysis. This may 
be attributable to smaller sample sizes as a correlation of sample size and the number 
of eQTL has been observed in the GTEx database (R2 = 0.83), but could also be due 
to the different data processing protocols. The four liver eQTL studies applied either 
microarrays or RNA-Seq to detect gene expression. The main difference of both 
techniques consists in the measurement type and the following quantification. 
Microarrays compare fluorescence signals of single probes with a given reference on 
the same chip, whereas RNA-Seq quantifies short reads and assembles them to 
transcripts, which requires a normalisation for each sample on the same flow cell. 
Independently from the measurement technique, gene expression data need always 
to be normalised to enable the comparison of different samples, even within the same 
dataset. This process complicates the evaluation of eQTL and their respective effect 
size, because an effect size of one dataset is often not comparable to effect sizes in 
other studies. For example, the eVariant rs7803454 regulates gene expression of 
PILRB in the liver database (effect size: 0.251) and the retinal eQTL database (effect 
size: 0.785), while it is impossible to make implications whether the effect is stronger 
in one of the tissues in comparison to the other. Several strategies could be applied to 
normalise effect sizes: (1) compare effect sizes to known physiological effects, or (2) 
scale gene expression values to a defined mean and SD. The first approach could be 
applied based on the eQTL rs10922109 – CFHR1 (effect size: 0.992, liver eQTL 
database) as several studies showed that rs10922109 shares a haplotype with the 
deletion of the genes CFHR1 and CFHR3 [123]. However, CFHR1 and CFHR3 are not 
ubiquitously expressed and defining an appropriate physiological effect as reference 
is challenging. The second approach was applied to compare the different tissues of 
the GTEx project, since exactly the same data measurement and processing protocol 
was used for all samples. However, the normalisation processes before eQTL 
calculation may always influence the comparability of effect sizes between datasets. 
Nevertheless, the effect direction seems to be a valuable criterion to evaluate eQTL 
with respect to their potential physiological impact because its algebraic sign is 
independent of gene expression processing. 
Furthermore, the measurement of gene expression in 314 retinal tissue samples 
originating from three independent study sites revealed that 2,412 genes were 
exclusively detected in only one or two of the studies. It is important to remark, that 
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even if comparable measurement methods and the exact same raw data analysis 
pipeline were applied, hidden batch effects may influence results in single datasets 
[124,125]. Therefore, data of one study site should always be assessed in comparison 
with other datasets, to avoid at best the detection of false positive results. Alternatively, 
false positive findings can be minimised by correcting for multiple testing. The 
investigation of local eQTL in retina for example required adjustment for over 108.8 
million tests. So far, there is no gold standard for this procedure although several 
different adjustment approaches including Bayesian methods, permutation testing, and 
FDR calculation, are well accepted [126]. Adjustment for multiple testing gets even 
more complicated due to small eQTL effect sizes and the high variability of gene 
expression values between samples. All presented results in this thesis were based 
on stringent FDR thresholds to minimise detection of false positives, although some 
effects might remain unnoticed. 
As a first take home message, the comparison of effect sizes should always be 
performed with caution and should rather focus on effect directions, since these are 
independent of measurement and normalisation methods. Furthermore, combining 
single eQTL studies with further datasets omits findings caused by hidden confounders 
as well as batch effects and even enhances the potential to detect more effects 
because of the higher sample size. 
Evaluating the functional impact of eQTL is a highly discussed area facing several 
potential limitations: (1) mRNA abundance is only partly correlated with protein levels 
[40], (2) eQTL are frequently measured in post mortem tissue, which might not reflect 
the in vivo situation [127], (3) LD structures complicate the identification of true causal 
variants [128,129], and (4) the mechanisms underlying the eQTL signals often remain 
elusive [39]. Addressing these questions requires further methods and model systems. 
One of the most recent developments in the genome-editing field was the introduction 
of the CRISPR/Cas9 system, which enables targeted alteration of DNA sequences. In 
this study two strategies were applied to investigate experimentally gene expression 
regulation events, identified in the 10q26 (ARMS2-HTRA1) locus. First, two sgRNAs 
combined with a Cas9 endonuclease expression cassette were transfected into 
HEK293T cells to introduce the genomic deletion of the 5,196 bp “minimal haplotype” 
region defined by Grassmann et al. (2017) [25]. Thereafter, the deletion was 
successfully detectable via PCR reactions based on genomic DNA. Nevertheless, 
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gene expression of the previously bioinformatically predicted target genes showed no 
difference in modified single cell clones. The second approach aimed to enhance the 
computationally predicted effects using the dCas9-VPR construct generated by 
Chavez et al. (2015) [66]. The required protocol was first established in HEK293T cells 
by replicating the findings of Chavez et al. After generating a 113-fold enhancement of 
MIAT expression, dCas9-VPR was also applied in the minimal haplotype region at 
10q26. Again, no alterations in gene expression of the predicted target genes were 
observed.  
The failed replication of the bioinformatical hypothesis may be attributable to various 
reasons. The immortalised HEK293T cell line was chosen because of its comparably 
simple handling and the known high transfection efficiency. However, it is derived from 
embryonic kidney cells and might not reflect the physiological background of the GTEx 
post mortem samples. It was further seen as a promising model system because the 
observed eQTL were traceable in many tissues and most of the rs3750846-associated 
eGenes were known to be expressed in HEK293T cells. Another complication may be 
caused by the complexity of the minimal haplotype since it contains a 3,105 bp 
genomic repeat region harbouring multiple short interspersed nuclear elements 
(SINEs). This area is not specifically targetable by sgRNAs because genome editing 
might also affect additional loci. Furthermore, other studies previously reported gene 
expression regulation events caused by SINEs [130–132]. In addition, the minimal 
haplotype region is poorly covered by databases concerning chromatin conformation 
and accessibility [133], which could reveal potential mechanisms causing the distant 
eQTL effects. In general, prediction of the introduced molecular alterations caused by 
the deletion of the minimal haplotype region is challenging because the effect sizes of 
the beforehand calculated eQTL cannot be included in the evaluation. eQTL provide 
information about changes in gene expression based on allelic differences of specific 
variants. Deleting the whole genomic region around the variant generates a situation 
which is therefore not covered by eQTL. The affected gene regulation network might 
be seriously altered, whereby compensatory effects could also occur, especially if 
important pathways like the complement system are involved [134]. 
The very first successful in vitro CRISPR/Cas9 application investigating local eQTL 
was published in 2019 by Schrode and colleagues [68]. They altered the eVariant 
rs4702 in NGN2 excitatory neurons derived from human induced pluripotent stem cells 
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and replicated a beforehand identified eQTL in brain tissue [135]. The allelic 
conversion of rs4702 from AA to GG enabled to further explore the eQTL driving 
mechanisms in this locus and to assess its functional consequences. Nevertheless, 
allelic conversion was so far only applied to one specific local eQTL and its success 
rate might depend on the investigated genomic region and the respective haplotype 
structure. Another promising approach to explore eQTL in vitro and to resolve LD 
structures is based on cloning short genomic sequences around eVariants in front of a 
minimal promoter followed by a barcoded open reading frame. The generated 
constructs are then introduced into cultured cells, which are incubated for several 
hours. Next, DNA and RNA are isolated and compared to each other. The ratio of both 
provides information regarding the transcriptional influence of the eVariant. This 
approach can be further applied considering different alleles and various variants in 
one locus to resolve LD structures and to accurately identify regulatory DNA motifs. 
Ulirsch et al. first described this protocol to shed light on GWAS variants of red blood 
cell traits and called it massively parallel reporter assay [129].  
Altogether, developing methods for the functional validation of eQTL is highly relevant 
because eQTL do often not allow direct implications on the underlying biological 
mechanisms. Genome editing techniques enable targeted modification of genomic 
DNA and facilitate the generation of new model systems. Nevertheless, validating 
distant eQTL remains a complex task, which was not achieved so far. The generated 
hypothesis regarding the ARMS2-HTRA1 locus requires further investigations. This 
might be achieved with the help of other eQTL databases and by refinement of the 
applied in vitro models. 
Besides the identification of rs3750846 in the ARMS2-HTRA2 locus, Fritsche et al. 
(2016) detected 51 additional AMD-associated IHs distributed over 33 loci. Many of 
the 18 secondary but independent signal variants in a respective locus showed very 
low MAFs (< 1 %) and are usually not covered in other studies due to MAF thresholds 
or unreliable imputation. At first, investigation of potential disease relevant gene 
expression regulatory events was performed by searching eQTL databases for 
disease-associated variants. In case of AMD, 31 respectively 41 IHs were covered in 
the generated liver and retina databases. Eight IHs, distributed over 5 loci, were 
eVariants in liver and regulated the expression of altogether 15 unique eGenes. In 
contrast, seven IHs, each positioned in another locus, regulated 13 unique eGenes in 
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retinal tissue. Compared to retina, 6 AMD-associated variants were exclusively 
eVariants in liver tissue: rs10922109 (IH 1.1), rs570618 (IH 1.2), rs61818925 (IH 1.6), 
rs2043085 (IH 23.1), rs2070895 (IH 23.2), and rs17231506 (IH 24.2). These eVariants 
regulate the expression of 10 eGenes, with 5 eGenes known to be involved in 
complement activation (CFH, CFHR1, CFHR4, CFHR3, and CFHR5) and two genes 
being relevant for HDL metabolism (LIPC and CETP). Notably, the liver constitutes the 
main tissue for synthesis of systemic complement factors and blood lipids [136–138]. 
In contrast, a general interpretation of the five IHs being an eVariant in retinal but not 
in liver tissue remains complex, since no clearly shared pathways are detectable 
between the genes HLA-DQB1, TSBP1-AS1, BX842242.1, AC009779.3, MT3, 
RSPRY1, GNAO1, and TMEM199. Interestingly, two IHs are eVariants in both 
databases: rs6565597 (IH 27) regulates three genes in liver (TSPAN10, ACTG1, and 
ANAPC11) and one in retinal tissue (ARL16). The second shared eVariant rs7803454 
(IH 11) regulates the genes PILRA and PILRB with the same effect direction in both 
organs and two further genes exclusively in retinal tissue: STAG3L5P and ZCWPW1. 
PILRA and PILRB proteins are known to function as antagonists within the PTPN6 
pathway and have been previously investigated in the context of AD [139,140]. 
Remarkably, Kikuchi et al. (2019) identified chromatin looping as a key event for gene 
expression regulation in this locus [141].  
In general, it is recommended to investigate gene expression regulation in tissues, 
which are mechanistically relevant for the disease of interest [54]. AMD is a disease of 
the posterior pole and it is widely anticipated that the choroid, the RPE, and the retina 
are mainly involved in pathogenic processes concerning late-stage AMD [142]. 
Regarding these tissues, to-date solitary expression data of the retina are available in 
large scale and only 7 of the 52 (13.5 %) AMD-associated IHs were eVariants in the 
results presented in this thesis. In contrast, a recent study regarding schizophrenia, 
obviously a brain-related disease, revealed that 51 of 106 (48.1%) schizophrenia-
associated GWAS lead variants are eVariants in brain tissue [143]. In consequence, 
the rarely observed gene expression regulation by AMD-associated variants in retinal 
tissue raises the hypothesis that the retina is not the primary site of AMD pathology. 
However, no conclusion can be drawn for the choroid or the RPE since no eQTL data 
regarding these tissues are available to-date. 
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Furthermore, gene expression regulation effects occurring in single tissues are difficult 
to interpret since most proteins are only characterised regarding their general function. 
Information about potential tissue-specific interaction partners or molecular roles 
remains elusive. Additionally, proteins often show different tissue- and cell type-
specific isoforms, which are again rarely characterised.  
In case of AMD, retina-specific regulation of gene expression was only rarely observed 
in this study. In contrast, many changes in expression were detected in pathways 
relevant for the many bodily cells or tissues, like the complement and the blood lipid 
system. For these reasons, an alternative approach was used to elucidate the potential 
role of AMD-associated variants in AMD aetiology. Instead of investigating tissue-
specific eGenes, a TWAS was performed to identify significantly AMD-associated 
genes in multiple tissues. The usefulness of TWAS was already shown for various 
complex phenotypes, like pancreatic cancer [144], lung cancer [145], or autism 
spectrum disorder [146]. In the present study, a TWAS was performed based on the 
individual genetic background of 16,144 late-stage AMD cases and 17,832 non-AMD 
controls, a dataset from the IAMDGC. This method represents an unbiased approach 
since gene expression imputation was not informed about the AMD status. In addition, 
the analysis was not restricted to AMD-associated IHs, but instead considered all 
possible local gene expression regulation events. This, in the end, enabled to identify 
genes associated with AMD genetics, which were not located in significant GWAS loci 
of previous studies. The TWAS including 27 tissues identified 106 genes, being AMD-
associated in at least one tissue. Remarkably, 10 of 15 (66.7 %) eGenes in the liver 
eQTL database regulated by AMD-associated variants were also identified by the 
TWAS analysis. Three of these genes (F13B, ALDH1A2, and LIPC) were exclusively 
AMD-associated in liver tissue. This underscores the validity of the TWAS approach to 
also cover single eQTL findings. However, it should be mentioned that a small 
proportion (83 of 588, 14.1 %) of the liver database samples were included in both 
studies, the liver eQTL mega-analysis and the TWAS. 
Nevertheless, the TWAS approach also has limitations, which become particularly 
apparent in the ARMS2-HTRA1 locus, since ARMS2 expression was found to be 
associated with AMD. As described earlier, several studies point to ARMS2 expression 
being potentially not causative for the AMD GWAS signal at this locus, since 
rs2736911, which results in a truncated ARMS2 protein, was never found to be 
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associated with AMD [22,147]. These findings are not recognised by the TWAS 
because of the extensive LD structure and the highly significant AMD-associations of 
variants in this locus. The results regarding gene expression regulation should 
therefore always be evaluated in the context of other studies and experiments. 
Furthermore, the TWAS did not include RPE or choroid tissue, which might be highly 
relevant for AMD pathology. 
Altogether, 54 genes were AMD-associated in multiple tissues, which points to non-
tissue-specific processes and pathways. However, a pathway enrichment analysis of 
the 54 genes failed to identify prominent processes. Quite the contrary, a large number 
of AMD-associated genes seem not to exclusively take part in the highly discussed 
AMD relevant pathways: (1) the complement system, (2) blood lipid levels, or (3) the 
extracellular matrix, as proposed by other studies [12,18].  
It is important to note that the TWAS and all eQTL studies in this thesis were based on 
healthy tissue and do not allow implications on disease mechanisms after AMD onset. 
Especially since cell type compositions may change, as occurring in AMD-associated 
retinal degeneration, which could result in different expression profiles throughout AMD 
stages. This was already observed for RPE and choroid tissue via single-cell RNA-Seq 
[148]. Interestingly, Ratnapriya et al. (2019) found no significant difference in gene 
expression of AMD affected and healthy donor eyes and therefore analysed eQTL in 
a merged dataset [70]. However, the undetectable differences in gene expression may 
be contributable to the normalisation methods, which were based on an extensive list 
of 3,804 “housekeeping” genes [149]. Nevertheless, the 54 AMD-associated genes 
provide help to generate new hypotheses regarding AMD aetiology and highlight, that 
individuals with high genetic burden for AMD are expected to show gene expression 
changes across multiple tissues outside the retina. 
In line with the identification of genes associated with AMD genetics in multiple tissues 
are the discoveries of several studies, which found correlations between the genetic 
risk of AMD and other complex phenotypes [121,150,151]. This indicates, that genetic 
variants which contribute to AMD risk potentially have pleiotropic effects. Therefore, a 
follow up study based on the TWAS results analysed the 106 AMD-associated genes 
according to a physical overlap of their genomic position with GWAS loci of 82 complex 
phenotypes [122]. This comparison highlights 50 of 106 (47.2 %) genes that have 
relevance for AMD aetiology and that potentially affect at least one other phenotype. 
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Of course, co-localization with a GWAS signal is not a functional evidence as such, but 
these genes are a priori candidate genes to be relevant for disease formation of other 
phenotypes besides AMD. Altogether, 15 AMD-associated genes are located in loci 
associated with neurological diseases. 10 genes overlap with GWAS loci of metabolic 
traits and nine genes with autoimmune diseases [122]. 
A remarkable observation is that only 2 AMD-associated genes (RDH5 and COL4A3) 
overlapped with loci of other complex eye diseases and traits [122]. This finding reflects 
the results of the retinal eQTL database. Only three eGenes of AMD-associated 
variants are also regulated by GWAS variants of other ocular phenotypes. Kiel et al. 
(2017) made the observation that genes associated with AMD in general do not overlap 
with genes relevant for other retinopathies [152]. Taken together, genes which 
expression is associated with AMD genetics often show an altered expression in 
various tissues. Furthermore, these genes are frequently located in GWAS loci of other 
complex phenotypes or traits. 
In conclusion, three new comprehensive databases were generated in this thesis to 
allow the investigation of gene expression regulation based on genetics of complex 
diseases and traits. The first database represents a meta study of four earlier published 
datasets from liver tissue and established an up-to-date data processing and 
normalisation protocol. This enabled the re-analysis of data collected up to ten years 
ago. The second database represents the largest eQTL study in healthy retinal tissue 
to-date. Both data repositories identified thousands of regulatory effects and were 
published in open access journals to enable extensive evaluations regarding diverse 
hypotheses. Furthermore, a third database including multiple tissues was processed 
to support recent and future projects at the Institute of Human Genetics Regensburg.  
All generated data in this thesis were evaluated in the context of AMD genetics. Taken 
together, AMD-associated variants have been shown to regulate gene expression of 
numerous genes. Remarkably, many of these genes are genetically regulated in 
multiple tissues, which raises the hypothesis that a large part of AMD risk is 
accompanied by differential gene expression throughout the entire body. Furthermore, 
AMD-associated genes seem to be also relevant for many other complex phenotypes, 




We should be aware, however, that gene expression is only one molecular phenotype 
of interest to investigate for disease-associated variants. Presently, various new QTL 
studies are emerging [153]. Moreover, novel model systems and experimental setups 
are required to validate bioinformatical findings. Especially targeted genome editing 
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Adipose subcutaneous 321 32,045 954,180 584,487 167,434 16,715 461,840 289,459 79,581 4,567 
Adipose visceral omentum 264 31,581 595,155 388,048 97,814 12,853 283,576 183,326 44,112 3,127 
Adrenal gland 148 28,134 331,389 232,064 48,876 9,491 145,933 96,500 21,272 2,124 
Artery aorta 232 29,666 654,296 426,728 105,377 13,631 305,367 199,792 47,714 3,510 
Artery coronary 124 28,114 226,321 159,227 31,389 7,843 107,489 67,125 14,553 1,697 
Artery tibial 325 29,980 823,197 536,865 140,427 15,255 393,223 264,563 66,432 4,071 
Brain amygdala 80 26,228 145,176 103,764 12,462 5,855 56,194 34,406 4,149 1,303 
Brain anterior cingulate cortex 102 27,042 188,474 138,586 20,135 6,898 77,660 51,462 7,277 1,471 
Brain caudate basal ganglia 129 28,780 266,517 194,531 31,300 9,606 119,976 76,873 12,115 2,185 
Brain cerebellar hemisphere 114 28,521 398,574 256,283 54,530 11,613 167,590 99,206 23,458 2,750 
Brain cerebellum 144 30,637 563,368 359,234 87,436 14,881 245,695 147,380 35,925 3,917 
Brain cortex 124 28,410 331,768 234,420 43,009 11,836 135,445 91,158 14,818 3,007 
Brain frontal cortex 112 27,599 222,449 160,231 27,499 8,569 94,837 61,781 10,581 1,869 
Brain hippocampus 98 27,336 157,948 112,752 16,450 5,463 71,681 43,024 7,061 1,173 
Brain hypothalamus 101 28,334 173,870 122,671 20,117 6,575 78,546 47,527 8,844 1,376 
Brain nucleus accumbens basal 
ganglia 
118 28,500 232,540 162,429 27,222 8,372 96,635 64,121 11,170 1,815 
Brain putamen basal ganglia 101 26,761 201,573 141,451 20,410 7,487 92,215 53,811 9,047 1,572 
Brain spinal cord cervical 74 26,519 130,781 96,802 12,381 5,272 58,247 34,556 5,167 1,179 
Brain substantia nigra 72 25,943 113,778 84,726 10,280 5,143 46,369 27,536 4,707 1,090 
Breast mammary tissue 206 32,201 462,591 303,878 74,630 11,010 207,952 136,398 32,067 2,539 
Cells EBV-transformed 
lymphocytes 
93 24,521 210,273 157,696 23,797 7,673 80,240 56,250 9,685 1,901 
Supplements 
108 
Cells transformed fibroblasts 251 26,660 552,611 375,885 86,698 11,266 254,916 175,691 36,856 2,875 
Colon Sigmoid 184 29,760 416,410 282,974 63,590 11,670 183,867 122,002 27,729 2,835 
Colon transverse 204 31,085 378,260 256,162 60,334 9,659 177,658 117,144 26,195 2,196 
Esophagus gastroesophageal 
junction 
187 29,224 448,797 299,682 70,054 11,832 204,653 134,764 29,459 2,880 
Esophagus mucosa 310 31,367 758,704 489,631 122,935 15,218 363,028 235,892 58,529 4,027 
Esophagus muscularis 280 29,935 823,304 529,158 140,087 15,161 394,017 258,413 62,865 4,106 
Heart atrial appendage 224 29,081 518,888 348,663 82,143 11,972 240,167 160,478 38,948 2,912 
Heart left ventricle 233 26,849 432,501 294,186 65,593 10,348 206,252 136,333 31,253 2,416 
Liver 131 26,072 207,257 148,804 26,972 7,089 94,855 59,750 13,002 1,560 
Lung 327 34,430 797,053 491,156 133,491 15,342 383,640 234,379 64,676 3,937 
Minor salivary gland 72 28,031 123,766 90,070 12,902 5,963 51,200 30,727 5,405 1,387 
Muscle skeletal 418 27,964 843,838 539,895 143,661 14,397 413,546 268,277 68,225 3,873 
Nerve tibial 305 33,801 1,085,095 665,219 191,680 18,647 518,420 327,117 90,081 5,408 
Ovary 96 28,610 200,460 139,210 24,185 7,107 85,188 51,142 10,612 1,588 
Pancreas 174 27,931 524,816 363,890 81,784 12,348 235,522 159,041 34,454 3,245 
Pituitary 148 32,261 398,450 259,858 61,107 11,772 175,493 109,696 25,661 2,687 
Prostate 107 30,583 215,608 147,542 28,252 7,306 90,094 56,577 11,928 1,598 
Skin not sun exposed 
Suprapubic 
279 33,014 743,789 476,612 123,179 15,395 349,547 224,596 58,678 3,929 
Skin sun exposed lower leg 365 33,940 1,028,424 623,890 183,930 18,133 492,538 310,346 87,672 5,037 
Small intestine terminal ileum 102 29,667 154,391 108,823 20,377 5,741 62,724 38,319 8,279 1,159 
Spleen 114 29,403 345,287 249,183 48,509 10,444 142,080 97,621 18,226 2,592 
Stomach 190 30,497 334,985 230,703 46,490 9,547 152,316 100,470 20,160 2,128 
Testis 197 42,810 599,548 403,791 94,666 18,773 263,356 180,254 37,793 4,768 
Thyroid 342 34,789 1,244,473 737,431 224,902 19,890 605,649 369,950 107,122 5,886 
Uterus 81 27,613 158,240 107,643 17,652 6,279 66,922 36,792 7,528 1,514 
Vagina 88 29,030 150,503 107,535 14,549 6,135 69,917 40,730 7,561 1,585 




Supplementary Table 2: Statistically significant AMD-associated genes (Q-Value < 0.001) of the TWAS analysis 









0.001) Mean beta (SD) Strongest effect tissue*** 
C1orf21 1:184356192-184598154 none 27 15 1 -0.028 Liver 
KCNT2 1:196194909-196578355 1 27 6 6 -0.052 (0.014) Nerve Tibial 
CFH 1:196621008-196716634 1 27 12 11 -0.052 (0.049) Nerve Tibial 
CFHR3 1:196743925-196763203 1 21 20 20 0.117 (0.055) Liver 
CFHR1 1:196788887-196801319 1 25 15 14 0.105 (0.084) Liver 
CFHR4 1:196819371-196888102 1 2 2 2 0.132 (0.128) Liver 
F13B 1:197008321-197036397 1 3 1 1 0.025 Testis 
ASPM 1:197053258-197115824 1 24 2 1 0.036 Skin Not Sun Exposed Suprapubic 
ZBTB41 1:197122810-197169672 1 27 5 5 0.03 (0.023) Brain Cerebellum 
RP11.332L8.1 1:197191352-197192385 1 22 1 1 -0.017 Artery Tibial 
DENND1B 1:197473878-197744826 1 27 6 1 0.007 Esophagus Mucosa 
LHX9 1:197881037-197904608 1 6 2 1 -0.035 Liver 
CD55 1:207494853-207534311 none 27 17 3 -0.016 (0.003) Esophagus Muscularis 
CR2 1:207627575-207663240 none 15 3 1 -0.013 Muscle Skeletal 
NOSTRIN 2:169643049-169722024 none 27 18 1 -0.015 Esophagus Mucosa 
PPIL3 2:201735630-201754026 none 27 27 16 0.037 (0.004) Adipose Subcutaneous 
NDUFB3 2:201936156-201950473 none 27 6 4 0.005 (0.001) Adipose Subcutaneous 
COL4A3 2:228029281-228179508 2 27 7 2 -0.023 (0.011) Nerve Tibial 
TBC1D23 3:99979844-100044095 4 27 13 4 -0.017 (0.013) Adrenal Gland 
NIT2 3:100053545-100075710 4 27 17 5 -0.013 (0.005) Lung 
RP11.114I8.4 3:100080031-100080481 4 27 8 2 0.009 (0.001) Thyroid 
TOMM70A 3:100082275-100120036 4 27 14 2 0.013 (0.012) Nerve Tibial 
TMEM45A 3:100211463-100296288 4 27 11 1 -0.011 Adrenal Gland 
CCDC109B 4:110481361-110609784 5 27 3 1 -0.012 Adipose Visceral Omentum 
Supplements 
110 
CASP6 4:110609875-110624739 5 27 5 3 0.021 (0.006) Heart Atrial Appendage 
PLA2G12A 4:110631145-110651233 5 27 15 13 0.021 (0.007) Esophagus Mucosa 
CFI 4:110661852-110723335 5 27 2 1 -0.01 Adipose Subcutaneous 
ADAM19 5:156822607-157002783 none 27 21 12 -0.013 (0.006) Adipose Subcutaneous 
IP6K3 6:33689444-33714762 none 27 17 1 0.019 Cells Transformed fibroblasts 
PPP2R5D 6:42952237-42979831 9 27 7 2 -0.013 (0.004) Stomach 
ZKSCAN1 7:99613204-99639312 11 27 8 1 -0.007 Artery Aorta 
STAG3 7:99775186-99818169 11 27 10 1 -0.007 Adipose Subcutaneous 
PMS2P1 7:99927805-99939531 11 27 17 14 -0.013 (0.005) Testis 
STAG3L5P 7:99934035-99947781 11 27 27 27 0.039 (0.006) Artery Tibial 
PILRB 7:99949799-99965356 11 27 27 27 0.042 (0.004) Adipose Subcutaneous 
PILRA 7:99971068-99997719 11 27 26 26 0.038 (0.006) Brain Cerebellum 
ZCWPW1 7:99998476-100026415 11 27 9 3 0.016 (0.005) Nerve Tibial 
TSC22D4 7:100060982-100076902 11 27 14 8 0.014 (0.007) Thyroid 
NYAP1 7:100081550-100092422 11 27 7 3 -0.017 (0.007) Skin Sun Exposed Lower leg 
RP11.325F22.5 7:104558007-104567077 10 23 3 1 0.013 Adipose Subcutaneous 
RP11.325F22.2 7:104581510-104602781 10 25 10 1 0.003 Adipose Visceral Omentum 
TNFRSF10A 8:23048189-23082639 12 27 20 14 -0.018 (0.008) Cells Transformed fibroblasts 
TRPM3 9:73143979-74061751 14 18 6 1 0.022 Testis 
RORB 9:77112281-77308093 13 24 4 1 -0.01 Cells Transformed fibroblasts 
TGFBR1 9:101866320-101916474 15 27 4 1 0.009 Whole Blood 
ZFP37 9:115800660-115819039 none 27 10 1 -0.017 Adipose Subcutaneous 
FGFR2 10:123237848-123357972 18 27 5 1 -0.021 Skin Not Sun Exposed Suprapubic 
ATE1 10:123499939-123688316 18 27 20 2 0.024 (0.009) Stomach 
TACC2 10:123748709-124014060 18 27 13 1 -0.034 Breast Mammary Tissue 
BTBD16 10:124030821-124097677 18 25 23 14 0.02 (0.033) Brain Cerebellum 
PLEKHA1 10:124134212-124191867 18 27 19 18 -0.051 (0.033) Brain Cerebellum 
ARMS2 10:124214169-124216868 18 26 14 14 -0.098 (0.09) Testis 
HTRA1 10:124221041-124274424 18 27 9 7 0.031 (0.068) Testis 
DMBT1 10:124320181-124403252 18 16 3 3 -0.02 (0.008) Skin Sun Exposed Lower leg 
Supplements 
111 
RP11.318C4.2 10:124516210-124558696 18 5 3 2 -0.011 (0.003) Skin Sun Exposed Lower leg 
RP11.107C16.2 10:124578332-124585965 18 6 2 1 -0.016 Skin Sun Exposed Lower leg 
RP11.564D11.3 10:124639246-124658230 18 18 3 1 0.012 Brain Cerebellum 
IKZF5 10:124750322-124768333 18 27 8 1 -0.031 Stomach 
ACADSB 10:124768495-124817827 18 27 6 1 -0.014 Adipose Subcutaneous 
RP11.777F6.3 11:87034801-87035401 none 27 2 1 0.007 Testis 
CEP57 11:95523129-95565857 none 27 23 3 -0.02 (0.005) Skin Not Sun Exposed Suprapubic 
AP001877.1 11:95556681-95557336 none 27 24 8 -0.016 (0.006) Nerve Tibial 
BLOC1S1 12:56109828-56113871 19 27 12 1 0.006 Muscle Skeletal 
RDH5 12:56114151-56118489 19 27 23 17 -0.018 (0.005) Lung 
B3GALTL 13:31774073-31906413 21 27 21 5 0.013 (0.005) Heart Left Ventricle 
PLEKHH1 14:68000018-68056027 22 27 14 2 0.016 (0.007) Artery Aorta 
RIN3 14:92980118-93155339 none 27 13 1 0.018 Colon Sigmoid 
ALDH1A2 15:58245622-58790065 23 27 6 1 0.01 Liver 
LIPC 15:58702768-58861151 23 24 15 1 0.037 Liver 
ULK3 15:75128457-75135538 none 27 17 1 -0.01 Lung 
USP7 16:8985951-9058371 none 27 3 1 0.014 Muscle Skeletal 
MT1DP 16:56677617-56678698 24 27 4 1 0.014 Lung 
HERPUD1 16:56965960-56977798 24 27 8 2 -0.009 (0.004) Esophagus Mucosa 
CETP 16:56995762-57017757 24 27 5 4 -0.017 (0.006) Colon Transverse 
NLRC5 16:57023397-57117443 24 27 9 2 -0.037 (0.019) Cells Transformed fibroblasts 
GPR56 16:57644564-57698944 24 27 2 1 -0.009 Breast Mammary Tissue 
BCAR1 16:75262928-75301951 25 27 11 2 -0.011 (0.001) Brain Cerebellum 
CFDP1 16:75327596-75467383 25 27 25 4 -0.01 (0.006) Esophagus Muscularis 
TMEM170A 16:75476952-75499395 25 27 10 2 0.019 (0.001) Adrenal Gland 
TMEM97 17:26646121-26655351 26 27 12 2 0.016 (0.001) Breast Mammary Tissue 
POLDIP2 17:26674036-26684545 26 27 15 3 0.011 (0.01) Pituitary 
TMEM199 17:26684604-26690705 26 27 14 10 0.012 (0.004) Skin Sun Exposed Lower leg 
C17orf70 17:79506911-79520987 27 27 3 1 0.008 Artery Tibial 
NPLOC4 17:79523913-79604172 27 27 24 1 0.022 Testis 
Supplements 
112 
PDE6G 17:79617489-79630142 27 27 4 1 -0.025 Testis 
AC006273.5 19:782755-785080 29 27 2 1 0.007 Skin Not Sun Exposed Suprapubic 
MED16 19:867962-893218 29 27 9 3 0.022 (0.004) Muscle Skeletal 
GRIN3B 19:1000418-1009646 29 27 26 2 -0.012 (0.002) Whole Blood 
CNN2 19:1026298-1039068 29 27 13 1 -0.029 Whole Blood 
ABCA7 19:1040102-1065568 29 27 24 2 -0.028 (0.01) Whole Blood 
CTC.503J8.6 19:6210390-6212492 28 27 4 1 -0.01 Artery Tibial 
GTF2F1 19:6379580-6393992 28 27 15 1 -0.011 Colon Sigmoid 
GPR108 19:6729925-6737614 28 27 27 22 0.031 (0.008) Thyroid 
RELB 19:45504688-45541452 30 27 1 1 -0.008 Lung 
BLOC1S3 19:45682003-45685059 30 27 4 1 0.009 Esophagus Muscularis 
DMPK 19:46272975-46285810 30 27 16 1 0.008 Stomach 
FUT2 19:49199228-49209207 none 27 11 1 -0.009 Lung 
MAMSTR 19:49215999-49222978 none 27 9 1 0.007 Adrenal Gland 
LILRA3 19:54799854-54809952 none 26 23 1 -0.016 Colon Sigmoid 
SPATA25 20:44515128-44516274 31 27 5 1 0.013 Adipose Visceral Omentum 
NEURL2 20:44517264-44517526 31 27 7 1 0.022 Adipose Visceral Omentum 
PLTP 20:44527460-44540794 31 27 23 10 0.017 (0.006) Adipose Visceral Omentum 
SLC12A5 20:44651569-44688784 31 20 10 9 -0.011 (0.014) Lung 
PICK1 22:38452318-38471708 34 27 14 1 -0.015 Colon Sigmoid 
BAIAP2L2 22:38480896-38506677 34 27 7 2 -0.023 (0.01) Esophagus Mucosa 
CBY1 22:39052645-39069859 34 27 16 1 -0.009 Liver 
* Locus number according to Fritsche et al. (2016) [18]; ** Number of tissues in which gene expression is genetically regulated and imputable according to PredictDB 
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